

# CTAD

## 2025

Clinical Trials on Alzheimer's Disease

December 1-4, 2025  
San Diego, CA, United States



# FINAL PROGRAM\*

\* Subject to change.

Montpellier '08 • Las Vegas '09 • Toulouse '10 • San Diego '11 • Monte Carlo '12 • San Diego '13  
Philadelphia '14 • Barcelona '15 • San Diego '16 • Boston '17 • Barcelona '18 • San Diego '19 • Virtual '20  
Boston '21 • San Francisco '22 • Boston '23 • Madrid '24

[www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)  
Email: [ctad@ant-congres.com](mailto:ctad@ant-congres.com)

JPAD  
THE JOURNAL  
OF PREVENTION  
OF ALZHEIMER'S  
DISEASE



# TABLE OF CONTENTS

<b>Organizing &amp; Scientific Committees</b>	<b>03</b>
<b>Lifetime Achievement Award</b>	<b>04</b>
<b>Keynotes</b>	<b>05</b>
<b>Program at a glance</b>	<b>06</b>
<b>Scientific sessions</b>	<b>07</b>
Monday, December 1	07
Tuesday, December 2	09
Wednesday, December 3	15
Thursday, December 4	20
<b>Biotech Showcase Session Details</b>	<b>26</b>
<b>Early Career Investigator Showcase Details</b>	<b>29</b>
<b>Practical Details</b>	<b>32</b>
<b>Notes</b>	<b>33</b>

# CTAD Organizing Committee and Scientific Committee

Susan ABUSHAKRA (San Francisco, United States); Paul AISEN (San Diego, United States)\*; Rebecca E. AMARIGLIO (Boston, United States); Patricia ANDREWS (Nashville, United States); Sandrine ANDRIEU (Toulouse, France)\*; Davide ANGIONI (Toulouse, France); Laura D. BAKER (Winston-Salem, United States); Randall J. BATEMAN (St. Louis, United States); Karim BENNYS (Montpellier, France); Ram BISHNOI (Tampa, United States); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, United States); Maria CARRILLO (Chicago, United States); Mathieu CECCALDI (Marseille, France); Suzanne CRAFT (Winston-Salem, United States); Lucia CRIVELLI (Buenos Aires, Argentina); Jeffrey CUMMINGS (Las Vegas, United States); Steven DEKOSKY (Gainesville, United States); Michael C. DONOHUE (San Diego, United States); Rachelle DOODY (Houston, United States); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, United States); Howard FILLIT (New York, United States); Nick FOX (London, UK); Kristian Steen FREDERIKSEN (Copenhagen, Denmark); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Joshua GRILL (Los Angeles, United States); Michael GRUNDMANN (San Diego, United States); Harald HAMPEL (Nutley, United States); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Jakub HORT (Prague, Czech Republic); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, United States); Zaven KHACHATURIAN (Washington DC, United States); Miia KIVIPETO (Stockholm, Sweden); Yan LI (St. Louis, United States); Jorge J. LLIBRE GUERRA (St. Louis, United States); Constantine G. LYKETSOS (Baltimore, United States); Gad A. MARSHALL (Boston, United States); Adam MECCA (New Haven, United States); Lefkos T. MIDDLETON (London, UK)\*; José Luis MOLINUEVO (Valby, Denmark); Kyra O'BRIEN (Philadelphia, United States); Claire PAQUET (Paris, France); Robert PERNECZKY (Munich, Germany); Ronald PETERSEN (Rochester, United States); Elif PINAR COSKUN (Lexington, United States); Michael S. RAFII (San Diego, United States); Rema RAMAN (San Diego, United States); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, United States); Marwan SABBAGH (Phoenix, United States); Stephen SALLOWAY (Providence, United States); Pascual SANCHEZ-JUAN (Madrid, Spain); Nikolaos SCARMEAS (New York, United States); Rachel SCHINDLER (New York, United States); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, United States); Eric SIEMERS (Indianapolis, United States); Sietske SIKKES (Amsterdam, The Netherlands); Yong SHEN (Hefei, China); Jiong SHI (Hefei, China); Irina SKYLAR-SCOTT (Stanford, United States); Heather SNYDER (Chicago, United States); Maria SOTO (Toulouse, France); Reisa SPERLING (Boston, United States)\*; Yaakov STERN (New York, United States); Duygu TOSUN (San Francisco, United States); Jacques TOUCHON (Montpellier, France)\*; Maileen ULEP (Las Vegas, United States); Wiesje van Der FLIER (Amsterdam, The Netherlands); Christopher H. VAN DYCK (New Haven, United States); Bruno VELLAS (Toulouse, France); Prashanthi VEMURI (Rochester, United States); Michael W. WEINER (San Francisco, United States)\* Donna M. WILCOCK (Indianapolis, United States); Bengt WINBLAD (Stockholm, Sweden); Kirsten WRIGHT (Portland, United States); Jin-Tai YU (Shanghai, China)

\*Organizing Committee Member

# CTAD 2025

## Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research, is awarded to Takeshi Iwatsubo MD, PhD in recognition for his pioneering work in Alzheimer's Disease neuroimaging and neuropathology.



### Takeshi IWATSUBO

Director of the National Institute of Neuroscience, National Center of Neurology and Psychiatry, Professor of the University of Tokyo.

Chairman of the Japan Society for Dementia Research.

### Biography

Trained as a neurologist and neuropathologist, Dr. Iwatsubo has contributed to the study of human neurodegenerative diseases, particularly Alzheimer's and Parkinson's, using multidisciplinary approaches. He demonstrated that Ab42 is the initial species deposited in senile plaque amyloid, elucidated the process of  $\gamma$ -secretase complex formation, and identified phosphorylated  $\alpha$ -synuclein as a component of Lewy bodies. He was the Principal Investigator of the Japanese AD Neuroimaging Initiative (J-ADNI) and the Japanese Trial Ready Cohort for Prevention of Alzheimer's Disease (J-TRC), and currently is the PI of the Japanese Registry for AD-DMT. He is the recipient of the MetLife Award for Medical Research (2008), AAIC Lifetime Achievement Award (2010), the Potamkin Prize (2012), and the Medal with Purple Ribbon from the Japanese government (2024).



# CTAD 2025

## Keynotes



### Next Generation Anti-Amyloid Therapies... Shuttling Past the ARIA Risk

**Ronald B. DeMattos, PhD**, *Senior Vice President and Chief Scientific Officer for Neurobiology, Eli Lilly and Company – Indianapolis, IN (United States)*

Ronald B. DeMattos, Ph.D. is a Senior Vice President and Chief Scientific Officer for Neurobiology at Eli Lilly. Dr. DeMattos received his doctorate in molecular and cellular biochemistry (SUNY – Stony Brook, 1998) and performed a post-doctoral fellowship at Washington University School of Medicine (Holtzman Lab). Dr. DeMattos joined Eli Lilly in 2002 and has since held multiple scientific positions within Neuroscience Discovery over the last 20+ years. He discovered and developed numerous compounds that progressed to clinical studies in Alzheimer's disease patients, including Solanezumab, Donanemab (FDA-approved Kisunla), and Remternetug (Phase-3 ongoing). He currently leads multiple discovery projects while managing the Indianapolis Neurodegeneration Discovery group, whose mission is to develop novel first-in-class therapies for neurodegeneration and Alzheimer's disease.



### Enhancing Participation of Representative Populations in Alzheimer Disease Clinical Trials

**Sid O'Bryant, PhD**, *Principal Investigator of the Health & Aging Brain Study, The University of North Texas Health Science Center at Fort Worth – Fort Worth, TX (United States)*

Dr. Sid O'Bryant is the principal investigator of the Health & Aging Brain Study – Health Disparities (HABS-HD), the most comprehensive study of Alzheimer's disease among the three largest racial/ethnic groups in the U.S. ever conducted: African Americans, Hispanics, and non-Hispanic whites. The goal of HABS-HD is to understand the life-course factors—including biological, sociocultural, environmental, and behavioral—that influence Alzheimer's disease risk in later life. This work aims to create population-specific precision-medicine approaches to treat and prevent Alzheimer's disease. Dr. O'Bryant is also a global expert in using blood-based biomarkers to develop precision-medicine strategies for diagnosing and treating Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease in adults with Down Syndrome.



### From Real World Data to Clinical Trials: The Case for Investigating Semaglutide in Alzheimer's Disease

**Peter Johannsen, MD, PhD**, *International Medical Vice President, Novo Nordisk, Copenhagen (Denmark)*

Dr. Peter Johannsen is a board-certified neurologist with more than 30 years' experience in cognitive neurology and Alzheimer's trials. He joined Clinical Drug Development at Novo Nordisk in 2020. Dr. Johannsen is scientifically responsible for Novo Nordisk's neurology development programs, including Alzheimer's disease. He previously served as senior consultant neurologist at the Memory Clinic, Rigshospitalet, and the National Danish Dementia Research Centre, Copenhagen University Hospital, Denmark, gaining extensive experience from clinical trials in Alzheimer's disease from first-in-human to Phase III. He has published over 100 scientific papers and given more than 300 lectures on Alzheimer's disease treatment. He also served as vice-chairman of the Danish Alzheimer Association and as a board member of the European Alzheimer's Disease Consortium (EADC).

# Program at a glance

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

## ● Monday, December 1

- 3:30 p.m. CTAD25 Welcome Ceremony
- 3:50 p.m. CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research
- 4:00 p.m. **Introductory Lecture:** Alzheimer's Therapeutics: Past, Present, Future
- 4:20 p.m. **LATE BREAKING COMMUNICATIONS**
- 5:35 p.m. **SYMPOSIUM 1:** Trontinemab's path to Phase III – From proof-of-concept in the ongoing Brainshuttle™ AD study to the pivotal studies TRONTIER 1 and TRONTIER 2 in people with early-stage symptomatic Alzheimer's disease
- 6:15 p.m. **KEYNOTE 1:** Enhancing Participation of Representative Populations In Alzheimer Disease Clinical Trials
- 6:45 p.m. CTAD WELCOME RECEPTION with the Support of the Alzheimer's Association • Sapphire Foyer – Level 4

## ● Tuesday, December 2

- 7:35 a.m. **POSTER WALKING TOUR** • Indigo Ballroom – Level 2
- 8:35 a.m. **LATE BREAKING SYMPOSIUM 1:** The Global Neurodegeneration Proteomics Consortium: additional insights into ApoE, cellular aging clocks from the V1 Harmonized Dataset, and what's coming in V2
- 9:15 a.m. **KEYNOTE 2:** From Real World Data to Clinical Trials: The Case for Investigating Semaglutide in Alzheimer's Disease.
- 9:40 a.m. **ORAL COMMUNICATIONS**
- 10:25 a.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 1 & Early Career Investigators Showcase Session 1)
- 11:00 a.m. **SYMPOSIUM 2:** The U.S. POINTER Trial: Imaging, neurovascular, and sleep outcomes
- 11:40 a.m. **LATE BREAKING COMMUNICATIONS**
- 12:40 p.m. **LUNCH ON YOUR OWN**
- 1:30 p.m. **COFFEE BREAK IN THE POSTER HALL** • Indigo Ballroom – Level 2
- 1:40 p.m. **ORAL COMMUNICATIONS**
- 3:10 p.m. **ROUNDTABLE 1:** Charting the Path Forward for Combination Therapy in Alzheimer's Disease: Challenges, Considerations, and Collaborative Solutions
- 3:50 p.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 2 & Early Career Investigators Showcase Session 2)
- 4:20 p.m. **LATE BREAKING COMMUNICATIONS**
- 5:35 p.m. **ROUNDTABLE 2:** CTAD China Clinical Trials Roundtable
- 6:05 p.m. **End of the Conference Day**

## ● Wednesday, December 3

- 7:30 a.m. **POSTER WALKING TOUR** • Indigo Ballroom – Level 2
- 8:30 a.m. **LATE BREAKING COMMUNICATIONS**
- 9:30 a.m. **KEYNOTE 3:** Next Generation Anti-Amyloid Therapies... Shuttling Past the ARIA Risk
- 9:55 a.m. **ORAL COMMUNICATIONS**
- 10:55 a.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 3 & Early Career Investigators Showcase Session 3)
- 11:25 a.m. **ORAL COMMUNICATIONS** – Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease
- 12:35 p.m. **LUNCH ON YOUR OWN**
- 1:15 p.m. **COFFEE BREAK IN THE POSTER HALL** • Indigo Ballroom – Level 2
- 1:30 p.m. **SYMPOSIUM 3:** ALZNET: First Look at Real-World Use of Novel Alzheimer's Disease Therapies in the United States
- 2:10 p.m. **LATE BREAKING COMMUNICATIONS**
- 3:10 p.m. **LATE BREAKING SYMPOSIUM 2:** Lecanemab Subcutaneous Formulation for Treatment Initiation in Early Alzheimer's Disease: Optimizing Patient Care with a Potential New Option
- 3:50 p.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 4 & Early Career Investigators Showcase Session 4)
- 4:20 p.m. **ORAL COMMUNICATIONS**
- 5:05 p.m. **TOPLINE PHASE 3 RESULTS: SYMPOSIUM 4: TOPLINE RESULTS** from Evoke and Evoke+: Two Phase 3 Randomized Placebo-Controlled Trials of Semaglutide in Participants with Early-Stage Symptomatic Alzheimer's Disease
- 5:45 p.m. **End of the Conference Day**

## ● Thursday, December 4

- 7:30 a.m. **POSTER WALKING TOUR** • Indigo Ballroom – Level 2
- 8:30 a.m. **LATE BREAKING COMMUNICATIONS**
- 9:00 a.m. **ORAL COMMUNICATIONS** – AD CLINICAL TRIALS – PHASE 1
- 10:30 a.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 5)
- 11:00 a.m. **SYMPOSIUM 5:** Advancing the Science of Recruitment for Preclinical Alzheimer's Disease Clinical Trials
- 11:40 a.m. **ORAL COMMUNICATIONS**
- 12:25 p.m. **LUNCH ON YOUR OWN**
- 1:10 p.m. **COFFEE BREAK IN THE POSTER HALL**
- 1:25 p.m. **LATE BREAKING COMMUNICATIONS**
- 2:25 p.m. **ORAL COMMUNICATIONS**
- 3:55 p.m. **COFFEE BREAK AND POSTER SESSION** • Indigo Ballroom – Level 2 (Biotech Showcase Session 5)
- 4:30 p.m. **ORAL COMMUNICATIONS**
- 6:00 p.m. **End of the CTAD Conference**

# Monday, December 1

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

3:30 p.m.  
3:50 p.m.

## CTAD25 Welcome Ceremony

Paul Aisen, USC-ATRI - San Diego (United States) and Jacques Touchon, Montpellier University - Montpellier (France)

3:50 p.m.  
4:00 p.m.

## CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research

Presented to Takeshi Iwatsubo MD, PhD in recognition for his pioneering work in Alzheimer's Disease Neuroimaging and Neuropathology.

4:00 p.m.  
4:20 p.m.

## Introductory Lecture: Alzheimer's Therapeutics: Past, Present, Future

Paul Aisen, USC-ATRI - San Diego (United States)

4:20 p.m.  
5:35 p.m.

## LATE BREAKING COMMUNICATIONS

Moderators: Michael Weiner, UCSF - San Francisco (United States) and Takeshi Iwatsubo, Tokyo University -Tokyo (Japan)

4:20 p.m.

### LB1 – Plasma Biomarkers To Identify and Predict Early Amyloid Accumulation in Cognitively Unimpaired Individuals: Enrichment for Stratified Early-Stage Prevention Trials

Gemma Salvado<sup>1,2</sup> Niklas Mattsson-Carl<sup>1</sup> Shorena Janelidze<sup>1</sup> Erik Stomrud<sup>1</sup> Sebastian Palmqvist<sup>1</sup> Oskar Hansson<sup>1</sup>  
<sup>1</sup>Lund University - Lund (Sweden), <sup>2</sup>BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain)

4:35 p.m.

### LB2 – Anti-tau therapeutic antibody, etalanutug, reduces the novel biomarker plasma Emtbr tau243 in patients with DIAD

Kristin Wildsmith<sup>1</sup> Kanta Horie<sup>1,2</sup> Peter Boyd<sup>3</sup> Erica Andreozzi<sup>1</sup> Randall Bateman<sup>2</sup> Jin Zhou<sup>2</sup> Larisa Reyderman<sup>1</sup>  
<sup>1</sup>Eisai Inc. - Nutley (United States), <sup>2</sup>Washington University School of Medicine - St. Louis (United States), <sup>3</sup>Eisai Europe Ltd. - Hatfield (United Kingdom)

4:50 p.m.

### LB3 – Modulation of the p75 neurotrophin receptor in a phase 2a Alzheimer's disease trial reduces plasma p-tau217, engages the synaptic proteome, and preserves visuospatial cognition

Frank Longo<sup>1</sup>

<sup>1</sup>Pharmatrophix - Menlo Park (United States) <sup>2</sup>University of Gothenburg - Gothenburg (Sweden), <sup>3</sup>Lund University - Lund (Sweden)

5:05 p.m.

### LB4 – Diagnostic Performance of the FDA-cleared Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio Thresholds for the Detection of Amyloid Pathology

Alicia Algeciras-Schimnich<sup>1</sup> Susan Ashrafzadeh Kian<sup>1</sup> Ramiro Eduardo Rea Reyes<sup>2</sup> Daniel Figdore<sup>1</sup> Brian Burkett<sup>1</sup> Derek Johnson<sup>1</sup> Hugo Botha<sup>1</sup> Stuart Mccarter<sup>1</sup> Gregory Day<sup>3</sup> Jonathan Graff-Radford<sup>1</sup> Henrik Zetterberg<sup>2</sup> Joshua Bornhorst<sup>1</sup> Sterling Johnson<sup>2</sup> Ronald Petersen<sup>1</sup> Vijay Ramanan<sup>1</sup>

<sup>1</sup>Mayo Clinic - Rochester (United States), <sup>2</sup>Wisconsin Alzheimer's Disease Research Center - Wisconsin (United States), <sup>3</sup>Mayo Clinic - Jacksonville (United States)

5:20 p.m.

### LB5 – Clinical, Safety, and Biomarker Outcomes From a Post Treatment Observational Extension of the Phase 2 PROSPECT-ALZ Study of Ceperognastat in Early Symptomatic Alzheimer's Disease

Leanne Munsie<sup>1</sup> Adam Fleisher<sup>1</sup> Michele Mancini<sup>1</sup> Jiaying Guo<sup>1</sup> Hugh Nuthall<sup>1</sup> Diana Otero Svaldi<sup>1</sup> Vikas Kotari<sup>1</sup> Mike Hutton<sup>1</sup> Dustin J. Mergott<sup>1</sup> Mark Mintun<sup>1</sup> Oskar Hansson<sup>1</sup>

<sup>1</sup>Eli Lilly and Company - Indianapolis (United States)

# Monday, December 1

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

5:35 p.m.  
6:15 p.m.

## SYMPOSIUM 1

**Trontinemab's path to Phase III – From proof-of-concept in the ongoing Brainshuttle™ AD study to the pivotal studies TRONTIER 1 and TRONTIER 2 in people with early-stage symptomatic Alzheimer's disease**

Chair: Reisa Sperling, *Brigham and Women's Hospital - Massachusetts General Hospital - Boston (United States)*

**Presentation 1: Brainshuttle™ AD: New interim results of a randomized, placebo-controlled Phase Ib/IIa proof-of-concept study with trontinemab, a novel anti-amyloid monoclonal bispecific antibody for the treatment of Alzheimer's disease**

Luka Kulic, *F. Hoffmann-La Roche Ltd - Basel (Switzerland)*

**Presentation 2: TRONTIER 1 and 2: Rationale and design of two identical Phase III trials to assess the efficacy and safety of trontinemab in early symptomatic Alzheimer's disease**

Catherine Mummery, *Queen Square Institute of Neurology, UCL – London (United Kingdom)*

**Presentation 3: The TRAVELLER master pre-screener protocol: An approach to reduce participant burden and broaden access to clinical trials in Alzheimer's disease**

Christopher Lane, *Roche Products Ltd - Welwyn Garden City (United Kingdom)*

6:15 p.m.  
6:40 p.m.

## KEYNOTE 1

**Enhancing Participation of Representative Populations in Alzheimer Disease Clinical Trials**

Sid O'Bryant, *The University of North Texas Health Science Center at Fort Worth – Fort Worth, TX (United States)*

Introduction: Howard Feldman, *University of California San Diego, La Jolla (United States)*

6:45 p.m.  
7:45 p.m.

**CTAD WELCOME RECEPTION with the Support of the Alzheimer's Association**





# Tuesday, December 2

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

7:35 a.m.  
8:35 a.m.

## POSTER WALKING TOUR • *Indigo Ballroom – Level 2*

8:35 a.m.  
9:15 a.m.

### LATE BREAKING SYMPOSIUM 1

**The Global Neurodegeneration Proteomics Consortium: additional insights into ApoE, cellular aging clocks from the V1 Harmonized Dataset, and what's coming in V2**

Chair: Farhad Imam, *Gates Ventures – Seattle (United States)*

**Presentation 1: Proteomic signatures of the APOE  $\epsilon$ 4 and APOE  $\epsilon$ 2 genetic variants and Alzheimer's disease**  
Niklas Mattsson-Carlsson, *Lund University – Lund (Sweden)*

**Presentation 2: Plasma Proteomics Identifies Early-Life Differences in APOE e4/e4 Individuals Related to Key AD Biological Pathways**

Erik C. B. Johnson, *Emory University – Atlanta (United States)*

**Presentation 3: Cellular Aging Signatures in the Plasma Proteome Record Aging and Neurodegeneration**  
Daisy Yi Ding, *Stanford University – Stanford (United States)*

9:15 a.m.  
9:40 a.m.

### KEYNOTE 2

**From Real World Data to Clinical Trials: The Case for Investigating Semaglutide in Alzheimer's Disease**

**Peter Johannsen**, *Novo Nordisk - Copenhagen (Denmark)*

Introduction: **Bruno Vellas**, *IHU HealthAge, Toulouse (France)*

9:40 a.m.  
10:25 a.m.

### ORAL COMMUNICATIONS

Moderators: **Elif Pinar Coskun**, *University of Kentucky – Lexington, KY (United States)* and **Reisa Sperling**, *Harvard Medical School, Brigham and Women's Hospital – Boston, MA (United States)*

9:40 a.m.

**OC1 – The effect of herpes zoster vaccination at different stages of the dementia disease course: Implications for defining the study population of clinical trials**

Min Xie<sup>1</sup>, Markus Eytting<sup>1</sup>, Christian Bommer<sup>1</sup>, Haroon Ahmed<sup>2</sup>, **Pascal Geldsetzer<sup>1</sup>**

<sup>1</sup>Stanford University – Stanford (United States), <sup>2</sup>Cardiff University – Cardiff (United Kingdom)

9:55 a.m.

**OC3 – Biological staging of Alzheimer's disease using blood-based biomarkers**

**Gemma Salvadó<sup>1,2</sup>**, Kanta Horie<sup>3,4,5</sup>, Nicholas Barthélemy<sup>3,4</sup>, Suzanne E. Schindler<sup>4,6</sup>, Shorena Janelidze<sup>1</sup>, Anna Orduña Dolado<sup>1</sup>, Divya Bali<sup>1</sup>, Erik Stomrud<sup>1,7</sup>, Niklas Mattsson-Carlsson<sup>1,8,9</sup>, Sebastian Palmqvist<sup>1,7</sup>, Jacob W. Vogel<sup>10</sup>, Randall J. Bateman<sup>3,4,6,11</sup>, Rik Ossenkoppele<sup>1,12,13</sup>, Oskar Hansson<sup>1</sup>

<sup>1</sup>Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, - Lund (Sweden), <sup>2</sup>Barcelona eta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), <sup>3</sup>The Tracy Family SILQ Center, Washington University School of Medicine - St Louis (United States), <sup>4</sup>Department of Neurology, Washington University School of Medicine - St Louis (United States), <sup>5</sup>Eisai Inc. - Nutley (United States), <sup>6</sup>Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), <sup>7</sup>Memory Clinic, Skåne University Hospital - Malmö (Sweden), <sup>8</sup>Wallenberg Center for Molecular Medicine, Lund University - Lund (Sweden), <sup>9</sup>Department of Neurology, Skåne University Hospital - Lund (Sweden), <sup>10</sup>Department of Clinical Sciences Malmö, SciLifeLab, Lund University - Lund (Sweden), <sup>11</sup>Hope Center for Neurological Disorders, Washington University School of Medicine - St Louis (United States), <sup>12</sup>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), <sup>13</sup>Amsterdam Neuroscience, Neurodegeneration - Amsterdam (Netherlands)

10:10 a.m.

**OC4 – The SMART-HS Study: A Targeted Therapeutic Strategy for LATE Disease**

**E. Pinar Coskun<sup>1</sup>**, Ahmed Bahrani<sup>1</sup>, Lauren Bojarski<sup>1</sup>, Justin Barber<sup>1</sup>, Danica Coy<sup>1</sup>, Emily Smith<sup>1</sup>, Molly Harper<sup>1</sup>, Alexandra Curtis<sup>1</sup>, Erin Abner<sup>1</sup>, Brian Gold<sup>1</sup>, Linda Van Eldik<sup>1</sup>, Peter Nelson<sup>1</sup>, Gregory Jicha<sup>1</sup>

<sup>1</sup>University of Kentucky - Lexington (United States)

# Tuesday, December 2

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

10:25 a.m.  
11:00 a.m.

## COFFEE BREAK AND POSTER SESSION (Indigo Ballroom – Level 2)

 **Biotech Showcase Session 1 – Artificial Intelligence and Digital Innovation** (details P.26)

 **Early Career Investigators Showcase Session 1 – Translational Therapeutics and Clinical Innovation** (details P.29)

11:00 a.m.  
11:40 a.m.

## SYMPOSIUM 2

### The U.S. POINTER Trial: Imaging, neurovascular, and sleep outcomes

Chairs: Heather Snyder, Alzheimer Association, Chicago (United States), Rema Raman, ATRI-USC, San Diego (United States), and Kristina McLinden, National Institute on Aging, Baltimore (United States)

#### Presentation 1: U.S. POINTER Trial Outcomes: Results of the Imaging Ancillary Study

Susan Landau, UC Berkeley - Berkeley (United States)

#### Presentation 2: POINTER-NV: Results of the U.S. POINTER Neurovascular Ancillary Study

Tina E. Brinkley, Wake Forest University School of Medicine - Winston-Salem (United States)

#### Presentation 3: POINTER-zzz: Results of the U.S. POINTER Sleep Ancillary Study

Laura D. Baker, Wake Forest University School of Medicine - Winston-Salem (United States)

11:40 a.m.  
12:40 p.m.

## LATE BREAKING COMMUNICATIONS

Moderators: Rachel Whitmer, University of California, Davis - Davis (United States) and Laia Montoliu-Gaya, University of Gothenburg - Gothenburg (Sweden)

11:40 a.m.

### LB6 – Immunoassay-based p-tau205 is a biomarker of Tau-PET abnormality: a cross-sectional and longitudinal study

Juan Lantero-Rodriguez<sup>1</sup>, Shorena Janelidze<sup>2</sup>, Sebastian Palmqvist<sup>2</sup>, Luisa Sophie Braun-Wohlfahrt<sup>1</sup>, Jakub Vavra<sup>1</sup>, Niklas Mattsson-Carlgrén<sup>2</sup>, Erik Stomrud<sup>2</sup>, Henrik Zetterberg<sup>1</sup>, Kaj Blennow<sup>1</sup>, Oskar Hansson<sup>2</sup>, Gemma Salvadó<sup>2</sup>, Laia Montoliu-Gaya<sup>1</sup>

<sup>1</sup>University of Gothenburg - Gothenburg (Sweden), <sup>2</sup>Lund University - Lund (Sweden)

11:55 a.m.

### LB7 – Lumipulse plasma p-tau217/Aβ42 ratio: Accuracy across the spectrum of Alzheimer's disease neuropathologic changes

Stamatia Karagianni<sup>1,2</sup>, Alexis Moscoso<sup>1, 2, 3</sup>, Martijn Van Essen<sup>4</sup>, Ismini Mainta<sup>5</sup>, Valle Camacho<sup>6</sup>, Omar Rodríguez-Fonseca<sup>7</sup>, Andrés Perissinotti<sup>8, 9</sup>, Michel J. Grothe<sup>10, 11, 12</sup>, Valentina Garibotto<sup>5, 12</sup>, Michael Schöll<sup>1, 2, 4, 13</sup>

<sup>1</sup>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden), <sup>2</sup>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden), <sup>3</sup>Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n - Santiago De Compostela (Spain), <sup>4</sup>Department of Neuropsychiatry, Sahlgrenska University Hospital - Gothenburg (Sweden), <sup>5</sup>Division of Nuclear Medicine, Geneva University Hospitals - Geneva (Switzerland), <sup>6</sup>Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona - Barcelona (Spain), <sup>7</sup>Nuclear Medicine Department, Lucus Augusti University Hospital (HULA) - Lugo (Spain), <sup>8</sup>Nuclear Medicine Department, Hospital Clínic Barcelona - Barcelona (Spain), <sup>9</sup>Biomedical Research Networking Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), ISCIII - Barcelona (Spain), <sup>10</sup>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III - Madrid (Spain), <sup>11</sup>Reina Sofía Alzheimer's Centre, CIEN Foundation, ISCIII - Madrid (Spain), <sup>12</sup>Faculty of Medicine, University of Geneva and Center for Biomedical Imaging (CIBM) - Geneva (Switzerland), <sup>13</sup>Dementia Research Centre, Institute of Neurology, University College London - London (United Kingdom)

12:10 p.m.

## LB08 – Untargeted proteomics and machine learning reveal novel biomarker candidates capturing diverse perturbed pathways in Alzheimer's disease in an African American cohort

Lindsey Kuchenbecker<sup>1, 2</sup>, Kevin Thompson<sup>3</sup>, Cheyenne Hurst<sup>1</sup>, Yen-Ning Huang<sup>4, 5</sup>, Michael Heckman<sup>6</sup>, Minerva M. Carrasquillo<sup>1</sup>, Andrew Saykin<sup>4, 7, 8</sup>, John Lucas<sup>9</sup>, Floyd Willis<sup>10</sup>, Gregory Day<sup>11</sup>, Neill Graff-Radford<sup>11</sup>, Nilufer Ertekin-Taner<sup>11, 1</sup>, Kwangsik Nho<sup>12, 7, 13</sup>, Krishna Kalari<sup>14</sup>

<sup>1</sup>Department of Neuroscience, Mayo Clinic - Jacksonville (United States), <sup>2</sup>Center for Clinical and Translational Science, Mayo Clinic - Rochester (United States), <sup>3</sup>Department of Quantitative Health Sciences, Mayo Clinic - Rochester (United States), <sup>4</sup>Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine - Indianapolis (United States), <sup>5</sup>Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine - Indianapolis (United States), <sup>6</sup>Department of Quantitative Health Sciences, Mayo Clinic - Jacksonville (United States), <sup>7</sup>Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine - Indianapolis (United States), <sup>8</sup>Department of Medical and Molecular Genetics, Indiana University School of Medicine - Indianapolis (United States), <sup>9</sup>Department of Psychiatry and Psychology, Mayo Clinic - Jacksonville (United States), <sup>10</sup>Department of Family Medicine, Mayo Clinic - Jacksonville (United States), <sup>11</sup>Department of Neurology, Mayo Clinic - Jacksonville (United States), <sup>12</sup>Indiana University School of Medicine - Indianapolis (United States), <sup>13</sup>School of Informatics and Computing, Indiana University - Indianapolis (United States), <sup>14</sup>Mayo Clinic - Jacksonville (United States)

12:25 p.m.

## LB09 – Neuropathological insights into the effects of aducanumab on patients with Alzheimer's disease

Lindsay A. Welikovich<sup>1, 2</sup>, Derek H. Oakley<sup>1, 2</sup>, Rachel E. Bennett<sup>1, 2</sup>, Alberto Serrano-Pozo<sup>1, 2</sup>, Haoyang Zhu<sup>1</sup>, Nancy Ruiz-Urbe<sup>1, 2</sup>, Theodore J. Zang<sup>1, 2</sup>, Donald S. Marks<sup>3</sup>, Stephen Salloway<sup>4</sup>, Charles Bernick<sup>5</sup>, David Greeley<sup>6</sup>, Thierry Bussiere<sup>7</sup>, Edward D. Plowey<sup>7</sup>, C. Dirk Keene<sup>8</sup>, Bradley T. Hyman<sup>1, 2</sup>

<sup>1</sup>Massachusetts General Hospital - Boston (United States), <sup>2</sup>Harvard Medical School - Boston (United States), <sup>3</sup>Headlands Research Eastern MA - Plymouth (United States), <sup>4</sup>Warren Alpert Medical School of Brown University - Providence (United States), <sup>5</sup>Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas (United States), <sup>6</sup>Kingfisher Cooperative, LLC - Spokane (United States), <sup>7</sup>Biogen - Cambridge (United States), <sup>8</sup>University of Washington - Seattle (United States)

12:40 p.m.  
1:20 p.m.

## LUNCH ON YOUR OWN

1:20 p.m.  
1:40 p.m.

## COFFEE BREAK IN THE POSTER HALL (Indigo Ballroom – Level 2)

1:40 p.m.  
3:10 p.m.

## ORAL COMMUNICATIONS

Moderators: Sandrine Andrieu, IHU HealthAge and INSERM – Toulouse, (France) and Mark Espeland, Wake Forest University School of Medicine – Winston Salem, NC (United States)

1:40 p.m.

## OC5 – The Effects of Lecanemab Treatment on Soluble CSF A $\beta$ Protofibrils in Clarity AD

Kanta Horie<sup>1</sup>, Akihiko Koyama<sup>1</sup>, Pallavi Sachdev<sup>1</sup>, Kazuyoshi Shuta<sup>2</sup>, Kazuhiro Tahara<sup>2</sup>, Michio Kanekiyo<sup>1</sup>, Shobha Dhadda<sup>1</sup>, Larisa Reyderman<sup>1</sup>, Steven Hersch<sup>1</sup>, Michael Irizarry<sup>1</sup>, Lynn Kramer<sup>1</sup>

<sup>1</sup>Eisai Inc. - Nutley (United States), <sup>2</sup>Eisai Co., Ltd. - Tsukuba (Japan)

1:55 p.m.

## OC6 – Impact of a 10-Year Multidomain Lifestyle Intervention on Long-Term Risks for Cognitive Impairment: The Look AHEAD Program

Mark Espeland<sup>1</sup>, Rebecca Neiberg<sup>1</sup>, Haiying Chen<sup>1</sup>, Stephen Rapp<sup>1</sup>, Bonnie Sachs<sup>1</sup>, Chinedu Udeh-Momoh<sup>1</sup>, Laura Baker<sup>1</sup>, Kathleen Hayden<sup>1</sup>, Denise Houston<sup>1</sup>, Jose Luchsinger<sup>2</sup>, Rena Wing<sup>3</sup>, Sevil Yasar<sup>4</sup>, Lynne Wagenknecht<sup>1</sup>

<sup>1</sup>Wake Forest University School of Medicine - Winston Salem (United States), <sup>2</sup>Columbia University Irving Medical Center - New York (United States), <sup>3</sup>The Miriam Hospital - Providence (United States), <sup>4</sup>Johns Hopkins School of Medicine - Baltimore (United States)

2:10 p.m.

## OC7 – Outcomes from the BetterBrains Trial, a multi-domain, person-centred, dementia risk factor management randomised controlled trial to prevent cognitive decline

Emily Rosenich<sup>1</sup>, Darshini Ayton<sup>1</sup>, Stephanie Pirota<sup>1</sup>, Hannah Cummins<sup>1</sup>, Maya Norfolk<sup>1</sup>, Nawaf Yassi<sup>2</sup>, Shantha Rajaratnam<sup>1</sup>, Richard Sinnott<sup>2</sup>, Matthew Pase<sup>1</sup>, Amy Brodtmann<sup>1</sup>, Ashley Bush<sup>3</sup>, Leonid Churilov<sup>2</sup>, Anna Barker<sup>1</sup>, Paul Maruff<sup>4</sup>, Yen Ying Lim<sup>1</sup>

<sup>1</sup>Monash University - Melbourne (Australia), <sup>2</sup>University of Melbourne - Melbourne (Australia), <sup>3</sup>Florey Institute - Melbourne (Australia), <sup>4</sup>Cogstate Ltd - Melbourne (Australia)

# ● Tuesday, December 2

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

2:25 p.m.

## OC8 – Quantifying tau knockdown in individuals with Alzheimer’s Disease receiving intrathecal tau MAPT antisense oligonucleotide NI0752 using Stable Isotope Labelling Kinetics (SILK) – interim analysis of a phase 1B randomised, double-blinded, placebo-controlled, multicentre trial

Aram Aslanyan<sup>1,2</sup>, Chihiro Sato<sup>3, 4</sup>, Donald Elbert<sup>5</sup>, Catherine Mummery<sup>1, 2</sup>, Nupur Ghoshal<sup>3</sup>, Eric Mcdade<sup>3</sup>, Randall Bateman<sup>3, 4, 6</sup>, **Ross Paterson**<sup>1, 2, 4, 7</sup>

<sup>1</sup>Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London - London (United Kingdom), <sup>2</sup>National Hospital for Neurology and Neurosurgery - London (United Kingdom), <sup>3</sup>Department of Neurology, Washington University School of Medicine in St Louis - St. Louis (United States), <sup>4</sup>The Tracy Family Stable Isotope Labeling Quantitation Center, Washington University School of Medicine, Washington University in St. Louis - St. Louis (United States), <sup>5</sup>Department of Neurology, University of Washington - Seattle (United States), <sup>6</sup>Dominantly Inherited Alzheimer Network, Washington University in St. Louis - St. Louis (United States), <sup>7</sup>Darent Valley Hospital - Dartford (United Kingdom)

2:40 p.m.

## OC9: Insights into Clinical Trial Recruitment: An Analysis of Prescreening Data from the AHEAD Study

Dylan Kirn<sup>1,2</sup>, Shunran Wang<sup>3</sup>, Karin Ernstrom<sup>3</sup>, Joshua D. Grill<sup>4,5</sup>, Gustavo Jimenez-Maggiora<sup>3</sup>, Doris Molina-Henry<sup>3</sup>, Paul Aisen<sup>3</sup>, Reisa Sperling<sup>1, 2</sup>, Rema Raman<sup>3</sup>

<sup>1</sup>Department of Neurology, Brigham and Women’s Hospital - Boston (United States), <sup>2</sup>Department of Neurology, Massachusetts General Hospital - Boston (United States), <sup>3</sup>Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States), <sup>4</sup>Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), <sup>5</sup>Department of Psychiatry and Human Behavior, University of California Irvine - Irvine (United States)

2:55 p.m.

## OC10: Results from the open-label extension period of TOGETHER, a Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal–mild Alzheimer’s disease

William Byrnes<sup>1</sup>, Irene Rebollo Mesa<sup>2</sup>, Tim Buchanan<sup>3</sup>, Bart Van Den Steen<sup>3</sup>, Hans Van Tricht<sup>3</sup>, Katie Taiyari<sup>4</sup>, Omobola Famodimu<sup>5</sup>, Jos Bloemers<sup>6</sup>, **Saori Shimizu**<sup>7</sup>, Ute Massow<sup>8</sup>, Ralph P. Maguire<sup>3</sup>, Colin Ewen<sup>4</sup>

<sup>1</sup>UCB - Raleigh (United States), <sup>2</sup>UCB - Madrid (Spain), <sup>3</sup>UCB - Braine-L’alleud (Belgium), <sup>4</sup>UCB - Slough (United Kingdom), <sup>5</sup>UCB - Oakville (Canada), <sup>6</sup>UCB - Breda (Netherlands), <sup>7</sup>UCB - Brussels (Belgium), <sup>8</sup>UCB - Monheim Am Rhein (Germany)

3:10 p.m.

3:50 p.m.

## ROUNDTABLE 1

### Charting the Path Forward for Combination Therapy in Alzheimer’s Disease: Challenges, Considerations, and Collaborative Solutions

Chair: Howard Fillit, Alzheimer’s Drug Discovery Foundation - New York City (United States)

### Presentation 1: Add-On Combination Therapy with Monoclonal Antibodies: Implications for Drug Development

Jeffrey Cummings, Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, UNLV - Las Vegas, (United States)

### Presentation 2: Considerations in the Development and Use of Biomarkers for Combination Therapy in Alzheimer’s Disease

Suzanne Schindler, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine – St. Louis (United States)

### **Discussion:** Jeffrey Cummings (Moderator)<sup>1</sup>, Suzanne Schindler<sup>2</sup>, Howard Fillit<sup>3</sup>, Diana Gallagher<sup>4</sup>, Fred Grossman<sup>5</sup>

<sup>1</sup>Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada at Las Vegas, Las Vegas, NV (United States); <sup>2</sup>Department of Neurology, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO (United States); <sup>3</sup>Alzheimer’s Drug Discovery Foundation, New York, NY (United States); <sup>4</sup>Biogen, Cambridge, MA (United States); <sup>5</sup>Coya Therapeutics, Philadelphia, PA (United States)

# Tuesday, December 2

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

3:50 p.m.  
4:20 p.m.

## COFFEE BREAK AND POSTER SESSION (*Indigo Ballroom – Level 2*)

 **Biotech Showcase Session 2 – Digital and Neurotechnology-Based Biomarkers and Therapeutics**  
(*details P.26*)

 **Early Career Investigators Showcase Session 2 – Biomarkers and Mechanisms of Frailty and Cognitive Decline** (*details P.29*)

4:20 p.m.  
5:35 p.m.

## LATE BREAKING COMMUNICATIONS

Moderators: Marwann Sabbagh, Barrow Neurological Institute – Phoenix, AZ (United States) and Jacques Touchon, Montpellier University – Montpellier (France)

4:20 p.m.

### LB10 – Pharmacokinetic / pharmacodynamic relationship of the gamma-secretase modulator nivegaceter in presymptomatic carrier participants of the PSEN1 E280A mutation

Agnès Poirier<sup>1</sup>, Enrique Gaspar<sup>1</sup>, Dominik Lott<sup>1</sup>, Stella Yilmaz<sup>1</sup>, Tianxu Yang<sup>2</sup>, Agnès Portron<sup>1</sup>, Kalbinder Mahil<sup>3</sup>, Tayo Bodede<sup>3</sup>, David Aguillón<sup>4</sup>, David Gordon<sup>5</sup>, Robert Alexander<sup>5</sup>, Thomas Mueggler<sup>1</sup>, Stefan Sturm<sup>1</sup>, Rosanna Tortelli<sup>1</sup>, Irene Gerlach<sup>1</sup>

<sup>1</sup>F. Hoffmann-La Roche Ltd - Basel (Switzerland), <sup>2</sup>F. Hoffmann-La Roche Ltd, Roche China Holding - Shanghai (China), <sup>3</sup>Roche Products Ltd, Welwyn Garden City - Welwyn (United Kingdom), <sup>4</sup>Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia - Medellín (Colombia), <sup>5</sup>Banner Alzheimer's Institute - Phoenix (United States)

4:35 p.m.

### LB11 – Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer's Disease Patients

Marwan Sabbagh<sup>1</sup>, Audrey Gabelle<sup>2</sup>, Timo Grimmer<sup>3</sup>, Juan Carlos Lopez-Talavera<sup>4</sup>, David Gould<sup>4</sup>, Wolfgang Liedtke<sup>4</sup>, William Chezem<sup>4</sup>, Kun Jin<sup>4</sup>, Christopher Missling<sup>4</sup>

<sup>1</sup>Barrow Neurological Institute - Phoenix (United States), <sup>2</sup>University of Montpellier - Montpellier (France), <sup>3</sup>Technical University of Munich, School of Medicine and Health, TUM University Hospital - Munich (Germany), <sup>4</sup>Anavex Life Sciences - New York (United States)

4:50 p.m.

### LB12– Plasma brain derived p-Tau217 outperforms other p-Tau biomarkers in identifying abnormal brain amyloid burden and predicts faster cognitive decline

Joyce Ruifen Chong<sup>1</sup>, Saima Hilal<sup>1</sup>, Narayanaswamy Venketasubramanian<sup>2</sup>, Michael Schöll<sup>3</sup>, Kaj Blennow<sup>3</sup>, Nicholas J. Ashton<sup>3</sup>, Henrik Zetterberg<sup>3</sup>, Christopher P. Chen<sup>1</sup>, Mitchell Kim Peng Lai<sup>1</sup>

<sup>1</sup>National University of Singapore - Singapore (Singapore), <sup>2</sup>Raffles Hospital - Singapore (Singapore), <sup>3</sup>University of Gothenburg - Gothenburg (Sweden)

5:05 p.m.

### LB13 – Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance– Estimating Accumulated or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials

Suzanne Hendrix<sup>1</sup>, John Whetten<sup>1</sup>, Kent Hendrix<sup>1</sup>, Sam Dickson<sup>1</sup>

<sup>1</sup>Pentara Corporation - Salt Lake City (United States)

5:20 p.m.

### LB14 – The value of earlier initiation of anti-amyloid therapy for AD

Jack M. Chapel<sup>1,2</sup>, Bryan Tysinger<sup>1,2</sup>, Hossein Pourmand<sup>1,2</sup>, Paul Aisen<sup>1,3</sup>, Dana Goldman<sup>1,2</sup>

<sup>1</sup>University of Southern California - Los Angeles (United States), <sup>2</sup>USC Schaeffer Institute for Public Policy & Government Service - Los Angeles (United States), <sup>3</sup>USC Alzheimer's Therapeutic Research Institute - San Diego (United States)

5:35 p.m.  
6:05 p.m.

## ROUNDTABLE 2

### CTAD CHINA CLINICAL TRIALS ROUNDTABLE

Chairs: Jiong Shi, The First Affiliated Hospital of USTC – Hefei (China), Yong Shen, USTC. Hefei (China), Jeffrey Cummings, UNLV, Las Vegas (United States),

### Presentation 1: Clinical Trials in the Chinese Population and Large-Scale clinical cohorts

Jiong Shi, The First Affiliated Hospital of USTC – Hefei (China)



**Presentation 2: Shanghai Action to Prevent the Elderly from Dementia SHAPE: a Funnel-like Stratified Process**

*Xia Li, Alzheimer's Disease and Related Disorders Center, Jiao Tong University, Shanghai (China)*

**Discussion: Clinical Trials in the Chinese Population and Large-Scale clinical cohorts and the AD alliance**

*Jiong Shi, The First Affiliated Hospital of USTC, Hefei (China)*

*Yong Shen, USTC. Hefei (China)*

*Yi Tang, Xuanwu Hospital, Capital Medical University, Beijing (China)*

*Xia Li, Shanghai Jiao Tong University, Shanghai (China)*

*Zao Han, Shanghai Medical Innovation and Development Foundation -Shanghai (China)*

*Jacques Touchon, University of Montpellier (France)*

*Bruno Vellas, IHU HealthAge, Toulouse (France)*

6:05 p.m.

**END OF THE CONFERENCE DAY**

7:30 a.m.  
8:30 a.m.

## POSTER WALKING TOUR • Indigo Ballroom – Level 2

8:30 a.m.  
9:30 a.m.

## LATE BREAKING COMMUNICATIONS

Moderators: Clive Ballard, University of Exeter – Exeter (United Kingdom) and Jorge Llibre-Guerra, Washington University St. Louis – St. Louis, MO (United States)

8:30 a.m.

### LB15– Alzheimer's Disease blood biomarkers measured through remote capillary sampling correlate with cognitive performance in older adults

Anne Corbett<sup>1</sup>, Millie Sander<sup>1</sup>, Nicholas Ashton<sup>2</sup>, Hanna Huber<sup>2</sup>, Freya Bateman<sup>1</sup>, Clive Ballard<sup>1</sup>

<sup>1</sup>University of Exeter - Exeter (United Kingdom), <sup>2</sup>University of Gothenberg - Gothenberg (United Kingdom)

8:45 a.m.

### LB16 – Stage-specific prognostic roles of plasma biomarkers in Alzheimer's Disease

Daeun Shin<sup>1</sup>, Jun Pyo Kim<sup>1</sup>, Hyemin Jang<sup>2</sup>, Jihwan Yun<sup>3</sup>, Eun Hye Lee<sup>4</sup>, Heekyung Kang<sup>1</sup>, Sohyun Yim<sup>1</sup>, Heekyung Park<sup>1</sup>, Sunghyun Kim<sup>1</sup>, Henrik Zetterberg<sup>5</sup>, Kaj Blennow<sup>5</sup>, Duk L Na<sup>1</sup>, Hee Jin Kim<sup>1</sup>, Sookyoung Woo<sup>1</sup>, Sang Won Seo<sup>1</sup>

<sup>1</sup>Samsung Medical Center - Seoul (Korea, Republic of), <sup>2</sup>Asan Medical Center - Seoul (Korea, Republic of), <sup>3</sup>Kyung Hee University Hospital - Seoul (Korea, Republic of), <sup>4</sup>Indiana Alzheimer Disease Research Center - Indianapolis (United States), <sup>5</sup>University of Gothenburg - Gothenburg (Sweden)

9:00 a.m.

### LB17 – Multi-biomarker Plasma Clocks for Predicting Alzheimer Disease Symptom Onset

Kellen Petersen<sup>1</sup>, Chengjie Xiong<sup>1</sup>, Yan Li<sup>1</sup>, Marta Milà-Alomà<sup>2</sup>, Duygu Tosun<sup>2</sup>, Benjamin Saef<sup>1</sup>, Leslie Shaw<sup>3</sup>, Jeffrey Dage<sup>4</sup>, Henrik Zetterberg<sup>5</sup>, David Holtzman<sup>1</sup>, John Morris<sup>1</sup>, Randall Bateman<sup>1</sup>, Anthony Bannon<sup>6</sup>, William Potter<sup>7</sup>, Suzanne Schindler<sup>1</sup>

<sup>1</sup>Washington University in St. Louis - St. Louis (United States), <sup>2</sup>University of California San Francisco - San Francisco (United States), <sup>3</sup>University of Pennsylvania University in St. Louis - Philadelphia (United States), <sup>4</sup>Indiana University School of Medicine - Indianapolis (United States), <sup>5</sup>University of Gothenburg - Gothenburg (Sweden), <sup>6</sup>AbbVie - Chicago (United States), <sup>7</sup>Philadelphia (United States)

9:15 a.m.

### LB18 – Longitudinal associations between Plasma p-tau217 and amyloid PET

Mahnaz Shekari<sup>1</sup>, Duygu Tosun<sup>2</sup>, Suzanne E Schindler<sup>3,4</sup>, Jeff L Dage<sup>5,6</sup>, Shaw Leslie<sup>7</sup>, William J Jagust<sup>1</sup>, Susan M Landau<sup>1</sup>

<sup>1</sup>Helen Wills Neuroscience Institute, University of California, Berkeley- Berkeley (United States), <sup>2</sup>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco (United States), <sup>3</sup>Department of Neurology, Washington University School of Medicine, St. Louis (United States), <sup>4</sup>Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine - St. Louis (United States), <sup>5</sup>Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA - Indianapolis (United States), <sup>6</sup>Department of Neurology, Indiana University School of Medicine - Indianapolis (United States), <sup>7</sup>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania - Philadelphia (United States)

9:30 a.m.  
9:55 a.m.

## KEYNOTE 3

### Next Generation Anti-Amyloid Therapies .....Shuttling Past the ARIA Risk

Ronald B. DeMattos, Eli Lilly and Company – Indianapolis, IN (United States)

Introduction: Reisa Sperling, Brigham and Women's Hospital - Massachusetts General Hospital - Boston (United States)

9:55 a.m.  
10:55 a.m.

## ORAL COMMUNICATIONS

Moderators: Marisa Denlinger, Banner Sun Health Research Institute – Sun City, AZ (United States) and Mike Weiner, UCSF – San Francisco, CA (United States)

9:55 a.m.

### OC11: Combining endogenous CSF MTBR-tau243 and plasma pTau217 enhances prediction of continuous regional tau PET burden in amyloid-positive early Alzheimer's disease

Viswanath Devanarayan<sup>1</sup>, Thomas Doherty<sup>2</sup>, Erica Andreozzi<sup>1</sup>, Kristin Wildsmith<sup>1</sup>, Pallavi Sachdev<sup>1</sup>, Kanta Horie<sup>1</sup>, Arnaud Charil<sup>1</sup>, Harald Hampel<sup>1</sup>, Lynn Kramer<sup>1</sup>, Shobha Dhadda<sup>1</sup>, Michael Irizarry<sup>1</sup>

<sup>1</sup>Eisai Inc. - Nutley (United States), <sup>2</sup>Eisai Inc. - Hatfield (United Kingdom)

10:10 a.m.

### OC12: Brain volume changes with gantenerumab: relationship with amyloid removal

**Matteo Tonietto<sup>1</sup>, Erica Silvestri<sup>1,2</sup>, Christopher Belder<sup>3,4</sup>, Frederik Barkhof<sup>3,5</sup>, Nick Fox<sup>3</sup>, Janice Smith<sup>6</sup>, Gregory Klein<sup>1</sup>**

<sup>1</sup>Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), <sup>2</sup>A\*P Consulting Ltd - Sandwich (United Kingdom), <sup>3</sup>Dementia Research Centre, UCL Queen Square Institute of Neurology - London (United Kingdom), <sup>4</sup>Department of Neurology, Royal Adelaide Hospital and Queen Elizabeth Hospital - Adelaide (Australia), <sup>5</sup>Department of Radiology & Nuclear Medicine - Amsterdam (Netherlands), <sup>6</sup>Roche Products Ltd - Welwyn Garden City (United Kingdom)

10:25 a.m.

### OC13: Head-to-head comparison of SWI and T2\*-weighted gradient echo MRI sequences to detect ARIA-H in the TRAILBLAZER-ALZ 6 trial of donanemab

**Diana Svaldi<sup>1</sup>, Alessandro Biffi<sup>1</sup>, Hong Wang<sup>1</sup>, Emel Serap Nery<sup>1</sup>, Chuning Gao<sup>1</sup>, Ming Lu<sup>1</sup>, Emily Collins<sup>1</sup>, Karolina Feakins<sup>1</sup>, Sergey Shcherbinin<sup>1</sup>, Dawn Brooks<sup>1</sup>, John Sims<sup>1</sup>**

<sup>1</sup>Eli Lilly and Company - Indianapolis (United States)

10:40 a.m.

### OC14: Longitudinal trajectories of plasma p tau217 in cognitively unimpaired older adults using a fully automated platform

**Marisa N. Denlinger<sup>1</sup>, Sterling C. Johnson<sup>2</sup>, Alpna Singh<sup>1</sup>, Taina Marques<sup>1</sup>, Rachael E. Wilson<sup>2</sup>, Ramiro E. Rea Ryes<sup>2</sup>, Antoine Leuzy<sup>1</sup>, Valentina Ghisays<sup>3</sup>, Robert C. Alexander<sup>3</sup>, Reisa A. Sperling<sup>4</sup>, Keith A. Johnson<sup>5</sup>, Paul A. Aisen<sup>6</sup>, Jessica B. Langbaum<sup>3</sup>, Eric M. Reiman<sup>3</sup>, Nicholas J. Ashton<sup>3</sup>**

<sup>1</sup>Banner Sun Health Research Institute - Sun City (United States), <sup>2</sup>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison - Madison (United States), <sup>3</sup>Banner Alzheimer's Institute - Phoenix (United States), <sup>4</sup>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, - Boston (United States), <sup>5</sup>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital - Boston (United States), <sup>6</sup>Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

10:55 a.m.

11:25 a.m.

### COFFEE BREAK AND POSTER SESSION (*Indigo Ballroom – Level 2*)

 **Biotech Showcase Session 3 – Blood-Based Diagnostics and Biomarkers** (*details P.27*)

 **Early Career Investigators Showcase Session 3 – Digital Health and New Tools for Early Detection** (*details P.29*)

11:25 a.m.

12:35 p.m.

### ORAL COMMUNICATIONS – Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease

Introduction by Chair: Howard Fillit, Alzheimer's Drug Discovery Foundation, New York, NY (United States)

11:35 a.m.

### OC15: Protein-based Diagnosis and Analysis of Co-Pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma Proteomic Classifier

**Ying Xu<sup>1,2</sup>, Daniel Western<sup>1,2</sup>, Gyujin Heo<sup>1,2</sup>, Kwangsik Nho<sup>3</sup>, Hamilton Oh<sup>4</sup>, Yike Chen<sup>1,2</sup>, Menghan Liu<sup>1,2</sup>, Katherine Gong<sup>1</sup>, Agustin Ruiz<sup>5,2</sup>, Maria Victoria Fernández<sup>6,1</sup>, David Bennett<sup>7,6,8</sup>, Tony Wyss-Coray<sup>9</sup>, Muhammad Ali<sup>1,2</sup>, Carlos Cruchaga<sup>1,2</sup>**

<sup>1</sup>Department of Psychiatry, Washington University School of Medicine - St Louis (United States), <sup>2</sup>NeuroGenomics and Informatics Center, Washington University School of Medicine - St Louis (United States), <sup>3</sup>Indiana University School of Medicine - Indianapolis (United States), <sup>4</sup>Icahn School of Medicine at Mount Sinai - New York (United States), <sup>5</sup>Ace Alzheimer Center Barcelona - Barcelona (Spain), <sup>6</sup>CIBERNED, National Institute of Health Carlos III - Madrid (Spain), <sup>7</sup>Rush Alzheimer's Disease Center, Rush University Medical Center - Chicago (United States), <sup>8</sup>Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, - San Antonio (United States), <sup>9</sup>Wu Tsai Neurosciences Institute, Stanford University - California (United States)

11:50 a.m.

### OC16: Identifying and stratifying Alzheimer's disease using circular RNA biomarkers in blood

**Bridget Phillips<sup>1, 2, 3</sup>, Jessie Sanford<sup>1, 2, 3</sup>, Devin Dikec<sup>1, 2, 3</sup>, Menghan Liu<sup>1, 2, 3</sup>, Matt Johnson<sup>1, 2, 3</sup>, John Budde<sup>1, 2, 3</sup>, John Morris<sup>4, 5, 6</sup>, Nikolaos Mellios<sup>7</sup>, Alison Goate<sup>8</sup>, Alan Renton<sup>8</sup>, Dominantly Inherited Alzheimer Network Consortia<sup>9</sup>, Richard Perrin<sup>4, 5, 6</sup>, Laura Ibanez<sup>1, 2, 4</sup>, Carlos Cruchaga<sup>2, 1, 3</sup>**

<sup>1</sup>Department of Psychiatry, Washington University School of Medicine - St. Louis (United States), <sup>2</sup>NeuroGenomics and Informatics Center, Washington University School of Medicine - St. Louis (United States), <sup>3</sup>Hope Center for Neurological Disorders, Washington University School of Medicine - St. Louis (United States), <sup>4</sup>Department of Neurology, Washington University School of Medicine - St. Louis (United States), <sup>5</sup>Department of Pathology and Immunology, Washington University School of Medicine - St. Louis (United States), <sup>6</sup>Knight Alzheimer Disease Research Center, Washington University School of Medicine - St. Louis (United States), <sup>7</sup>Circular Genomics Inc - San Diego (United States), <sup>8</sup>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai - New York (United States), <sup>9</sup>Dominantly Inherited Alzheimer Network (DIAN) - St. Louis (United States)

12:05 p.m.

### OC17: Large-scale Plasma Proteomic Profiling Unveils Diagnostic Biomarkers and Pathways for Alzheimer's Disease

Heo Gyu Jin<sup>1</sup>, Ying Xu<sup>1</sup>, Jigyasha Timsina<sup>1</sup>, Daniel Western<sup>1</sup>, Carlos Cruchaga<sup>1</sup>

<sup>1</sup>Washington University - Saint Louis (United States)

12:20 p.m.

### OC18: Biomarkers Associated with Response to Treatment of Early Stage AD with Pepinemab, Anti-SEMA4D Blocking Antibody

Maurice Zauderer<sup>1</sup>, Elizabeth Evans<sup>1</sup>, Terrence Fisher<sup>1</sup>, Vikas Mishra<sup>1</sup>, Leslie Balch<sup>1</sup>, Elaine Gersz<sup>1</sup>, John Leonard<sup>1</sup>, Crystal Mallow<sup>1</sup>, Anton Porsteinsson<sup>2</sup>, Raymond Turner<sup>3</sup>, John Huffaker<sup>4</sup>

<sup>1</sup>Vaccinex, Inc. - Rochester (United States), <sup>2</sup>University of Rochester - Rochester (United States), <sup>3</sup>Georgetown University - Washington, DC (United States), <sup>4</sup>Neuropsychiatric Research Center - Southwest Florida (United States)

12:35 p.m.

1:15 p.m.

### LUNCH ON YOUR OWN

1:15 p.m.

1:30 p.m.

### COFFEE BREAK IN THE POSTER HALL (*Indigo Ballroom – Level 2*)

1:30 p.m.

2:10 p.m.

### SYMPOSIUM 3

#### ALZNET: First Look at Real-World Use of Novel Alzheimer's Disease Therapies in the United States

Chair: Reisa Sperling, Brigham and Women's Hospital - Massachusetts General Hospital - Boston (United States)

#### Presentation 1: ALZNET: An Update on Registry Growth and Collaborations

Maria C. Carrillo, Alzheimer's Association - Chicago (United States) on behalf of the ALZ-NET Study Team

#### Presentation 2: The ALZ-NET patient population: Demographics, Genetics and Biomarker Testing

Gil D. Rabinovici, Memory and Aging Center, UCSF - San Francisco (United States) on behalf of the ALZ-NET Study Team

#### Presentation 3: Longitudinal assessment of clinical and safety outcomes in participants receiving beta-amyloid targeting monoclonal antibodies: Real world therapy data from ALZ-NET

Michael S. Rafii, USC-ATRI - San Diego (United States) on behalf of the ALZ-NET Study Team

2:10 p.m.

3:10 p.m.

### LATE BREAKING COMMUNICATIONS

Moderators: Apostolos Manolopoulos, National Institute on Aging – NIH – Bethesda, MD (United States) and Rema Raman, Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

2:10 p.m.

#### LB19 –Foundation models for the early detection of Alzheimer's using cell-free DNA

Ravi Solanki<sup>1</sup>, Ivan Koychev<sup>2</sup>, Jonathan Wan<sup>2</sup>, Pouya Niki<sup>2</sup>, Christoforos Nalmpantis<sup>2</sup>, Javkhan-Ochir Ganbat<sup>2</sup>, Donal Byrne<sup>2</sup>, Henrik Zetterberg<sup>3</sup>, Masud Husain<sup>4</sup>, Sofia Toniolo<sup>4</sup>, Ivan Koychev<sup>2</sup>

<sup>1</sup>Prima Mente - San Francisco (United States), <sup>2</sup>Prima Mente - London (United Kingdom), <sup>3</sup>University of Gothenburg - Molndal (Sweden), <sup>4</sup>University of Oxford - Oxford (United Kingdom)

2:25 p.m.

#### LB20 – Performance of blood-based Screening algorithm for Predicting AD Pathology and Baseline Characteristics of Participants in a Phase 2 trial of Etanercept and Concurrent Lecanemab.

Thomas Doherty<sup>1</sup>, Devanarayan Viswanath<sup>2</sup>, Zhou Jin<sup>2</sup>, Wildsmith Kristin<sup>2</sup>, Charil Arnaud<sup>2</sup>, Pinner Kate<sup>1</sup>, Li David<sup>2</sup>, Sachdev Pallavi<sup>2</sup>, Reyderman Larisa<sup>2</sup>, Shobha Dhadha<sup>2</sup>, Michael Irizarry<sup>2</sup>

<sup>1</sup>Eisai Limited - Hatfield (United Kingdom), <sup>2</sup>Eisai Inc. - Nutley (United States)

2:40 p.m.

#### LB21 – Estimating The 10-Year Time-Savings Benefits of Lecanemab Treatment

John Whetten<sup>1</sup>, Sam Dickson<sup>1</sup>, Garrett Duncan<sup>1</sup>, Suzanne Hendrix<sup>1</sup>, Katherine Youmans-Kidder<sup>2</sup>, Daryl Jones<sup>2</sup>

<sup>1</sup>Pentara Corporation - Millcreek (United States), <sup>2</sup>Eisai Inc. - Nutley (United States)

2:55 p.m.

## LB22 – Neuron-derived extracellular vesicle-associated proBDNF and Complex V predict resilience to cognitive impairment

Apostolos Manolopoulos<sup>1</sup>, Roxanna Korologou-Linden<sup>2</sup>, Maja Mustapic<sup>1</sup>, Francheska Delgado-Peraza<sup>1</sup>, Pamela Yao<sup>1</sup>, Geraint Price<sup>2</sup>, Andrei Popescu<sup>3</sup>, Zoi Alexopoulou<sup>3</sup>, Janaky Coomaraswamy<sup>4</sup>, Janice Wong<sup>5</sup>, Gallen Triana-Baltzer<sup>6</sup>, Gerald Novak<sup>5</sup>, Oliver Robinson<sup>2</sup>, Lefkos Middleton<sup>2</sup>, Dimitrios Kapogiannis<sup>1</sup>

<sup>1</sup>Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH - Baltimore (United States), <sup>2</sup>Ageing Epidemiology Research Unit, School of Public Health, Imperial College London - London (United Kingdom), <sup>3</sup>Merck Sharp & Dohme - London (United Kingdom), <sup>4</sup>Takeda Pharmaceutical Company Ltd. - Cambridge (United States), <sup>5</sup>Johnson & Johnson - Cambridge (United States), <sup>6</sup>Johnson & Johnson - San Diego (United States)

3:10 p.m.

3:50 p.m.

## LATE BREAKING SYMPOSIUM 2

### Lecanemab Subcutaneous Formulation for Treatment Initiation in Early Alzheimer's Disease: Optimizing Patient Care with a Potential New Option

Chair: Sharon Cohen, Toronto Memory Program - Toronto (Canada)

#### Presentation 1: Rationale and Early Development of Subcutaneous Lecanemab

Larisa Reyderman, Eisai Inc., Nutley (United States)

#### Presentation 2: Safety Profile of a Subcutaneous Lecanemab Formulation

Michael Irizarry, Eisai Inc., Nutley (United States)

#### Presentation 3: Potential Benefits of a Subcutaneous Formulation of Lecanemab

Sharon Cohen, Toronto Memory Program - Toronto (Canada)

3:50 p.m.

4:20 p.m.

## COFFEE BREAK AND POSTER SESSION (Indigo Ballroom – Level 2)

🍷 **Biotech Showcase Session 4 – Multiomics and Precision Diagnostics** (details P.27)

🏠 **Early Career Investigators Showcase Session 4– Non-Pharmacological and Lifestyle Interventions** (details P.30)

4:20 p.m.

5:05 p.m.

## ORAL COMMUNICATIONS

Moderators: Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, CA (United States) and Suzanne Schindler, Washington University St. Louis, St. Louis, MO (United States)

4:20 p.m.

### OC19: Alpha-Synuclein Detection: A Versatile EV-Based Plasma Assay for Detecting Modified $\alpha$ -Synuclein in Synucleinopathies Without Pre-Enrichment

Carine Lim<sup>1</sup>, Hui Ling Ko<sup>1</sup>, Brian Minie<sup>1</sup>, Nicole Tsang<sup>1</sup>, Nicholas Ho<sup>1</sup>, Huilin Shao<sup>1</sup>, Richard Batrla<sup>2</sup>

<sup>1</sup>Sunbird Bio - Singapore (Singapore), <sup>2</sup>Sunbird Bio - Cambridge (United States)

4:35 p.m.

### OC20: Population characteristics and implications of implementation strategies for blood-based biomarkers in Alzheimer's disease across healthcare settings: Insights from a prospective, global, multicenter study

Imke Kirste<sup>1</sup>, Sayuri Hortsch<sup>2</sup>, Craig Ritchie<sup>3,4</sup>, Jeffery L. Dage<sup>5,6,7</sup>, Kristian Steen Frederiksen<sup>8,9</sup>, Marc Suárez-Calvet<sup>10</sup>, <sup>11,12</sup> Marwan N. Sabbagh<sup>13</sup>, Clara Quijano-Rubio<sup>14</sup>

<sup>1</sup>Roche Diagnostics Solutions - Indianapolis (United States), <sup>2</sup>Roche Diagnostics GmbH - Penzberg (Germany), <sup>3</sup>Scottish Brain Sciences - Edinburgh (United Kingdom), <sup>4</sup>Department of Medicine, University of St Andrews - St Andrews (United Kingdom), <sup>5</sup>Department of Neurology, Indiana University School of Medicine - Indianapolis (United States), <sup>6</sup>Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine - Indianapolis (United States), <sup>7</sup>Stark Neurosciences Research Institute, Indiana University School of Medicine - Indianapolis (United States), <sup>8</sup>Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet - Copenhagen (Denmark), <sup>9</sup>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen - Copenhagen (Denmark), <sup>10</sup>BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), <sup>11</sup>Hospital del Mar Research Institute - Barcelona (Spain), <sup>12</sup>Servei de Neurologia, Hospital del Mar - Barcelona (Spain), <sup>13</sup>Department of Neurology, Barrow Neurological Institute - Phoenix (United States), <sup>14</sup>Roche Diagnostics International Ltd - Rotkreuz (Switzerland)



# ● Wednesday, December 3

ALL SESSIONS WILL TAKE PLACE IN THE SAPPHIRE BALLROOM – LEVEL 4

4:50 p.m.

## OC21: Donanemab in Early Symptomatic Alzheimer's Disease: Additional Insights from the TRAILBLAZER-ALZ 2 Long-Term Extension

**Jennifer Zimmer**

*Eli Lilly and Company - Indianapolis (United States)*

5:05 p.m.

5:45 p.m.

## TOPLINE PHASE 3 RESULTS: SYMPOSIUM 4

### TOPLINE RESULTS from Evoke and Evoke+: Two Phase 3 Randomized Placebo-Controlled Trials of Semaglutide in participants with Early-Stage Symptomatic Alzheimer's Disease

Jeffrey L. Cummings<sup>1</sup>, Alireza Atri<sup>2, 3, 4</sup>, Howard H. Feldman<sup>5</sup>, Mary Sano<sup>6, 7</sup>, Wiesje Van Der Flier<sup>8, 9</sup>, Henrik Zetterberg<sup>10</sup>, Filip K. Knop<sup>11</sup>, Peter Johannsen<sup>11</sup>, Teresa León<sup>11</sup>, Rikke Mortensen Abschneider<sup>11</sup>, Philip Scheltens<sup>12, 13</sup>

<sup>1</sup>Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas - Las Vegas (United States), <sup>2</sup>Banner Sun Health Research Institute - Sun City (United States), <sup>3</sup>Banner Alzheimer's Institute, - Phoenix (United States), <sup>4</sup>Brigham and Women's Hospital, Harvard Medical School - Boston (United States), <sup>5</sup>Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California San Diego - La Jolla (United States), <sup>6</sup>Icahn School of Medicine at Mount Sinai - New York (United States), <sup>7</sup>James J Peters, VAMC - Bronx (United States), <sup>8</sup>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), <sup>9</sup>Amsterdam Neuroscience, Neurodegeneration, - Amsterdam (Netherlands), <sup>10</sup>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Mölndal (Sweden), <sup>11</sup>Novo Nordisk A/S - Copenhagen (Denmark), <sup>12</sup>Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam - Amsterdam Umc (Netherlands), <sup>13</sup>EQT Life Sciences - Amsterdam (Netherlands)

5:45 p.m.

## END OF THE CONFERENCE DAY

7:30 a.m.  
8:30 a.m.

## POSTER WALKING TOUR • *Indigo Ballroom – Level 2*

8:30 a.m.  
9:00 a.m.

## LATE BREAKING COMMUNICATIONS

Moderators: James Doecke, *The Australian e-Health Research Centre, CSIRO - Herston (Australia)* and Gustavo Jimenez-Maggiora, *University of Southern California - San Diego (United States)*

8:30 a.m.

### LB23 – Optimizing Blood-Based Alzheimer's Disease Diagnosis: A Multi-Marker pTau-217-Inclusive Approach

Jeremiah Hinson<sup>1,2</sup>, Johannes Eichner<sup>3</sup>, Muhammad Ali<sup>4</sup>, Crlos Cruchaga<sup>4</sup>, Timo Wittenberger<sup>3</sup>, Scott Levin<sup>5</sup>

<sup>1</sup>Danaher Diagnostics - Washington, DC (United States), <sup>2</sup>Johns Hopkins University School of Medicine - Baltimore, MD (United States), <sup>3</sup>GeneData - Basel (Switzerland), <sup>4</sup>Washington University St. Louis - St. Louis, MO (United States), <sup>5</sup>Danaher Diagnostics - Washington, DC (United States)

8:45 a.m.

### LB24 – pTau217 performance to separate Alzheimer's disease biological stage is not increased by adding demographic or clinical information

James Doecke<sup>1,2</sup>, Rodrigo Canovas<sup>3</sup>, Christopher Fowler<sup>4</sup>, Azadeh Feizpour<sup>4,5</sup>, Vincent Dore<sup>3,5</sup>, Ziad Saad<sup>6</sup>, Gallen Triana-Baltzer<sup>6</sup>, Manu Vandijck<sup>7</sup>, Gwendlyn Kollmorgen<sup>8</sup>, Clara Quijano-Rubio<sup>9</sup>, Jurgen Fripp<sup>1</sup>, Anthony Bannon<sup>10</sup>, Paul Maruff<sup>11</sup>, Christopher Rowe<sup>5</sup>, Colin Masters<sup>4</sup>

<sup>1</sup>The Australian e-Health Research Centre, CSIRO - Herston (Australia), <sup>2</sup>School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), <sup>3</sup>The Australian e-Health Research Centre, CSIRO - Parkville (Australia), <sup>4</sup>The Florey Institute of Neuroscience and Mental Health, the University of Melbourne - Parkville (Australia), <sup>5</sup>Department of Molecular Imaging & Therapy, Austin Health - Heidelberg (Australia), <sup>6</sup>Precision Measures, Johnson & Johnson - San Diego (United States), <sup>7</sup>Fujirebio Europe N.V. - Gent (Belgium), <sup>8</sup>Roche Diagnostics GmbH - Penzberg (Germany), <sup>9</sup>Roche Diagnostics International Ltd - Rotkreuz (Germany), <sup>10</sup>Abbvie - North Chicago (United States), <sup>11</sup>Cogstate - Melbourne (Australia)

9:00 a.m.  
10:28 a.m.

## ORAL COMMUNICATIONS – AD CLINICAL TRIALS – PHASE 1 SESSION

Moderators: Miranda E. Orr, *Washington University in St Louis - St. Louis (United States)* and Robert Rissman, *Translational Research Division and Biomarker Laboratory and Biorepository Director, Alzheimer's Therapeutic Research Institute – San Diego (United States)*

9:00 a.m.

### LB25 – Phase 1B/2A data from SORT-IN-2: Sortilin inhibition with VES001 in GRN mutation carriers was well-tolerated and elevated plasma and CSF progranulin

Mads Kjolby<sup>1</sup>, Nina Schultz<sup>1</sup>, Imogen Swift<sup>1</sup>, Ditte Mikkelsen<sup>1</sup>, Lærke Hedelund Fensbæk<sup>1</sup>, Louise Klem<sup>1</sup>, Sofie L. Frandsen<sup>1</sup>, Ove Pedersen<sup>1</sup>, Jacob Falck Hansen<sup>1</sup>, Anders Nykjaer<sup>1</sup>, Jonathan Rohrer<sup>2</sup>, Harro Seelaar<sup>3</sup>

<sup>1</sup>Vesper Bio - Copenhagen (Denmark), <sup>2</sup>University College London - London (United Kingdom), <sup>3</sup>Erasmus University Rotterdam - Rotterdam (Netherlands)

9:08 a.m.

### LB26 –Phase 1b/2a, 12-month, randomized, double-blind, placebo-controlled study of the safety/tolerability and preliminary evidence of efficacy of a tau anti-sense oligonucleotide in patients with tauopathies.

Lawren Vandevrede<sup>1</sup>, Hilary Heuer<sup>1</sup>, Courtney Lane-Donovan<sup>1</sup>, Peter Ljubenkovi<sup>1</sup>, Bruce Miller<sup>1</sup>, Julio Rojas<sup>1</sup>, Adam Boxer<sup>1</sup>

<sup>1</sup>Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco - San Francisco (United States)

9:16 a.m.

### LB27 – BQ-141, a First-in-Class Oral Tau Stabilizer, Robustly Inhibits Tau Spreading and Modulates Translational Biomarkers in a Seed-and-Spread Model

Markus Zweckstetter<sup>1</sup>

<sup>1</sup>brainQr Therapeutics GmbH - Goettingen (Germany)

9:24 a.m.

### OC22: A first-in-human double-blind, placebo-controlled, multiple ascending dose phase 1 study evaluating the safety and pharmacokinetics of PRX005/BMS-986446, a novel anti-MTBR tau monoclonal antibody, in healthy adults and patients with Alzheimer's disease

David P. Walling<sup>1</sup>, Ferenc Martenyi<sup>2</sup>, Brian Campbell<sup>2</sup>, Jun Lee<sup>2</sup>, Philip Dolan<sup>2</sup>, Donna Masterman<sup>2</sup>, Chad Swanson<sup>2</sup>, Mark Thomas<sup>3</sup>, Min Chen<sup>3</sup>, Aditi Shahane<sup>3</sup>, Nicholas Colletti<sup>3</sup>, Nanette Hock<sup>3</sup>, Ilena George<sup>3</sup>

<sup>1</sup>CenExel - Los Alamitos (United States), <sup>2</sup>Prothena - Brisbane (United States), <sup>3</sup>Bristol Myers Squibb - Princeton (United States)

9:32 a.m.

**OC23: First-in-Human Study of ADEL-Y01, a Monoclonal Antibody Targeting Acetylated Tau (ack280) in the MTBR: Safety and Pharmacokinetics in Healthy Adults and Early Alzheimer's Disease**

**Min-Seok Kim<sup>1,2</sup>, Yuna Oh<sup>1</sup>, Sungsil Lee<sup>3</sup>, Kyung-Hoon Hwang<sup>1</sup>, Young-Soo Sohn<sup>1</sup>, Dong-Sik Jung<sup>3</sup>, Taeyoung Yoon<sup>3</sup>, Peter J. Winkle<sup>4</sup>, Seung-Yong Yoon<sup>1,2</sup>**

<sup>1</sup>ADEL Institute of Science & Technology (AIST), ADEL, Inc. - Seoul (Republic of Korea), <sup>2</sup>Department of Brain Science, Asan Medical Center, University of Ulsan College of Medicine - Seoul (Republic of Korea), <sup>3</sup>Oscotec Inc. - Gyeonggi-Do (Republic of Korea), <sup>4</sup>CenExel ACT - Anaheim (United States)

9:40 a.m.

**OC24: Amyloid-related imaging abnormalities in an ongoing Phase 1 study of mivelsiran, an investigational RNA interference therapeutic targeting amyloid precursor protein, in patients with Alzheimer's disease**

**Neal S. Parikh<sup>1</sup>, Sharon Cohen<sup>2</sup>, Sandeep Chaudhari<sup>1</sup>, Lynn Farugia<sup>1</sup>, Andrew H. Ahn<sup>1</sup>, Julia Shirvan<sup>1</sup>, Steven M. Greenberg<sup>3</sup>**

<sup>1</sup>Alnylam Pharmaceuticals, Inc. - Cambridge (United States), <sup>2</sup>Toronto Memory Program - Toronto (Canada), <sup>3</sup>Harvard Medical School, Massachusetts General Hospital - Boston (United States)

9:48 a.m.

**OC25: Results of a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of VV7523, a tau-targeting therapeutic, in healthy adult participants**

**Elena Ratti<sup>1</sup>, Monroe Butler<sup>1</sup>, Naomi Muse<sup>1</sup>, Sarah Piantedosi<sup>1</sup>, Thrusha Chauhan<sup>1</sup>, Beth Mellen<sup>1</sup>, Joydip Kundu<sup>1</sup>, Vik Arora<sup>1</sup>, Albena Patroneva<sup>2</sup>, Maurice Emery<sup>2</sup>, Raj Rajagovindan<sup>1</sup>, Toby Ferguson<sup>1</sup>, Alfred Sandrock<sup>1</sup>**

<sup>1</sup>Voyager Therapeutics - Lexington (United States), <sup>2</sup>Voyager Therapeutics Contractor - Lexington (United States)

9:56 a.m.

**OC26: ABCA1-agonist treatment by CS6253 and effects on plasma total and isoform-specific apolipoprotein E in elderly men and women.**

**Jan Johansson<sup>1</sup>, Bengt Winblad<sup>2</sup>, Henrik Zetterberg<sup>3</sup>, Jeffrey Cummings<sup>4</sup>, Dobrin Nedelkov<sup>5</sup>, Hussein Yassine<sup>6</sup>**

<sup>1</sup>Artery Therapeutics, Inc. - San Ramon (United States), <sup>2</sup>Karolinska - Stockholm (Sweden), <sup>3</sup>Sahlgrenska - Gothenburg (Sweden), <sup>4</sup>U of Nevada - Las Vegas (United States), <sup>5</sup>Isoformix Inc. - Sugarland (United States), <sup>6</sup>USC - Los Angeles (United States)

10:04 a.m.

**OC27: Efficacy and safety of xanomeline and trospium chloride for cognitive impairment in Alzheimer's disease (MINDSET-1 and MINDSET-2)**

**Jeffrey L. Cummings<sup>1</sup>, William P. Horan<sup>2,3</sup>, Dongmei Liu<sup>3</sup>, Jessica Stanek<sup>3</sup>, Codrin Lungu<sup>3</sup>**

<sup>1</sup>University of Nevada - Las Vegas (United States), <sup>2</sup>University of California - Los Angeles (United States), <sup>3</sup>Bristol Myers Squibb - Princeton (United States)

10:12 a.m.

**OC28: SToMP and STAMINA Clinical Trials of Senolytics in Alzheimer's Disease Treatment and Prevention**

**Miranda E. Orr**, Washington University in St Louis - St. Louis (United States)

10:20 a.m.

**OC29: Pleiotropic Effects of the CNS-Selective M1 Muscarinic Agonist NSC001: From Rapid Symptomatic Relief to Long-Term Disease Modification in Alzheimer's Disease (AD)**

**Manfred Windisch<sup>1</sup>, Abraham Fisher<sup>2</sup>**

<sup>1</sup>NSC-Therapeutics GmbH - St. Radegund (Austria), <sup>2</sup>ADPD - Holon (Israel)

10:30 a.m.  
11:00 a.m.

**COFFEE BREAK AND POSTER SESSION (Indigo Ballroom – Level 2)**

 **Biotech Showcase Session 5 – Next-Generation Therapeutics (details P.28)**

11:00 a.m.  
11:40 a.m.

## SYMPOSIUM 5

### Advancing the Science of Recruitment for Preclinical Alzheimer's Disease Clinical Trials

Chair: Paul Aisen, USC-ATRI - San Diego (United States)

#### **Presentation 1: Impact of upcoming FDA enrollment requirements on recruitment for Alzheimer's disease clinical trials**

Lowell Schiller, Schaeffer Institute for Public Policy & Government Service – Washington, DC (United States)

#### **Presentation 2: Recruitment and screening in TRAILBLAZER-ALZ 3: A decentralized study of donanemab in preclinical Alzheimer's disease**

Karen C. Holdridge, Eli Lilly & Company – Indianapolis (United States)

#### **Presentation 3: Building a scalable and efficient recruitment funnel for preclinical Alzheimer's disease: The AHEAD 3-45 model**

Rema Raman, USC-ATRI, San Diego (United States)

11:40 a.m.  
12:25 p.m.

## ORAL COMMUNICATIONS

Moderators: [Iwata Atsushi](#), Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan) and [Heather M. Snyder](#), Alzheimer's Association, Chicago, IL (United States)

11:40 a.m.

#### **OC30: Interim analysis of post-marketing observational study of lecanemab in Japan**

[Iwata Atsushi](#)<sup>1</sup>, [Sakata Yukinori](#)<sup>2</sup>, [Koizumi Kinuyo](#)<sup>2</sup>, [Endo Akira](#)<sup>2</sup>, [Kuang Weijie](#)<sup>2</sup>, [Sumitomo Kenta](#)<sup>2</sup>, [Ishii Mika](#)<sup>2</sup>

<sup>1</sup>Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan), <sup>2</sup>Eisai Co., Ltd. - Tokyo (Japan)

11:55 p.m.

#### **OC31: Completion of a Phase 2 trial evaluating safety and efficacy of the synaptic regenerative small molecule SPG302 in participants with mild-to-moderate Alzheimer's disease**

[Bruce Brew](#)<sup>1</sup>, [Lauren Priest](#)<sup>2</sup>, [Aimee Cazyer](#)<sup>2</sup>, [Valerie Bramah](#)<sup>3</sup>, [Peter Vanderklisch](#)<sup>4</sup>, [Craig Erickson](#)<sup>4</sup>, [Sharron Gargosky](#)<sup>4</sup>, [Stella Saraff](#)<sup>4</sup>

<sup>1</sup>St Vincent's Hospital Sydney - Darlinghurst Nsw (Australia), <sup>2</sup>Flinders Medical Centre - Bedford Park Sa (Australia), <sup>3</sup>Flinders Medical Centre - Darlinghurst Nsw (Australia), <sup>4</sup>Spinogenix - Los Angeles (United States)

12:10 p.m.

#### **OC32: Breaking barriers in early Alzheimer's disease diagnosis: The power of the in vitro diagnostic Elecsys pT181p immunoassay in a population reflective of real-world clinical practice**

[Sayuri Hortsch](#)<sup>1</sup>, [David Caley](#)<sup>2</sup>, [Patrick Menzel](#)<sup>1</sup>, [Christopher Rowe](#)<sup>3</sup>, [Mark Rapp](#)<sup>4</sup>, [Dag Aarlsand](#)<sup>5</sup>, [Anna D Burke](#)<sup>6</sup>, [Clara Quijano-Rubio](#)<sup>7</sup>

<sup>1</sup>Roche Diagnostics GmbH - Penzburg (Germany), <sup>2</sup>Roche Diagnostics Limited - Burgess Hill (United Kingdom), <sup>3</sup>Australian Dementia Network Ltd - Melbourne (Australia), <sup>4</sup>Berman Clinical - New York (United States), <sup>5</sup>Kings College Hospital - London (United Kingdom), <sup>6</sup>Barrow Neurological Institute - Phoenix (United States), <sup>7</sup>Roche Diagnostics International Ltd - Rotkreuz (Switzerland)

12:25 p.m.  
1:10 p.m.

## LUNCH ON YOUR OWN

1:10 p.m.  
1:25 p.m.

## COFFEE BREAK IN THE POSTER HALL (Indigo Ballroom – Level 2)

1:25 p.m.  
2:25 p.m.

## LATE BREAKING COMMUNICATIONS

Moderators: [Denise Faustman](#), Massachusetts General Hospital/Harvard Medical School - Boston (United States) and [Lefkos Middleton](#), Imperial College London, London (United Kingdom)

1:25 p.m.

### **LB28 – Results of ASURE: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics and Exploratory Activity of T001 in Patients with Alzheimer's Disease**

Ronald Van Der Geest<sup>1</sup>, Anastasia Lili<sup>1</sup>, Oscar Van Loosbroek<sup>1</sup>, Andreia Almeida<sup>1</sup>, Frank Ruwe<sup>1</sup>, Alina Ciobanu<sup>1</sup>, Inez De Greef<sup>1</sup>, Charlotte Teunissen<sup>2</sup>, Sietske Sikkes<sup>3</sup>, Willem De Haan<sup>3</sup>, Jort Vijverberg<sup>3</sup>

<sup>1</sup>Treeway T001 AD BV - Tilburg (Netherlands), <sup>2</sup>Neurochemistry Laboratory, Department of Laboratory Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), <sup>3</sup>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands)

1:40 p.m.

### **LB29 – Impact of BCG Immunotherapy on Plasma p-tau217 in Patients with Type 1 Diabetes at Risk of Alzheimer's Disease: A Five-Year, Phase II, Randomized, Controlled Trial**

Shiho Hashiguchi<sup>1</sup>, Hikaru Hayashi<sup>2</sup>, Nicholas Kartsounis<sup>2</sup>, Daniel Mounier<sup>2</sup>, Serena Bradley<sup>2</sup>, Joan Braley<sup>2</sup>, Hui Zheng<sup>2</sup>, Willem Kühtreiber<sup>1</sup>, Denise Faustman<sup>1</sup>

<sup>1</sup>Massachusetts General Hospital/Harvard Medical School - Boston (United States), <sup>2</sup>Massachusetts General Hospital - Boston (United States)

1:55 p.m.

### **LB30 – Discovery of blood-based microRNAs that characterize Cerebral Amyloid Angiopathy**

David Salzman<sup>1</sup>, Anthony Bannon<sup>2</sup>

<sup>1</sup>Gatehouse Bio, Inc. - Natick (United States), <sup>2</sup>AbbVie - North Chicago (United States)

2:10 p.m.

### **LB31 – Results of the Phase 2b Trial of Neflamapimod in Dementia with Lewy Bodies**

John-Paul Taylor<sup>1</sup>, Stephen N Gomperts<sup>2</sup>, Lawrence S Honig<sup>3</sup>, Niels D Prins<sup>4</sup>, Amanda Gardner<sup>5</sup>, Kelly Blackburn<sup>5</sup>, John Alam<sup>5</sup>, James E Galvin<sup>6</sup>

<sup>1</sup>Newcastle University - Newcastle Upon Tyne (United Kingdom), <sup>2</sup>Massachusetts General Hospital - Charlestown (United States), <sup>3</sup>Columbia University Irving Medical Center - New York (United States), <sup>4</sup>Brain Research Center - Amsterdam (Netherlands), <sup>5</sup>CervoMed - Boston (United States), <sup>6</sup>CervoMed - Boca Raton (United States)

2:25 p.m.

### **ORAL COMMUNICATIONS**

3:55 p.m.

Moderators: Michael Rafii, Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States) and Ruben Smith, Lund University - Lund (Sweden)

2:25 p.m.

### **OC33: Effects of Semaglutide on Alzheimer's Disease-Related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer's Disease After 12 Weeks of Treatment**

Kristian Steen Frederiksen<sup>1,2</sup>, Marie Aare Bentsen<sup>3</sup>, Dylan Mathew Belmont-Rausch<sup>3</sup>, Lisbeth Carstensen<sup>3</sup>, Brian Cutler<sup>4</sup>, Redwan Farooq<sup>4</sup>, Lea Hildebrandt<sup>3</sup>, Martí Jiménez-Mausbach<sup>3</sup>, Peter Johannsen<sup>3</sup>, Gabriel Martino<sup>3</sup>, Joseph Poley-Wolf<sup>3</sup>, Amaya Zaratiegui<sup>3</sup>, Giovanni B Frisoni<sup>5,6</sup>, Kathrine E Attfield<sup>4</sup>, Lotte Bjerre Knudsen<sup>3</sup>

<sup>1</sup>Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet - Copenhagen (Denmark), <sup>2</sup>Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), <sup>3</sup>Novo Nordisk - Copenhagen (Denmark), <sup>4</sup>Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford - Oxford (United Kingdom), <sup>5</sup>Geneva Memory Center, Geneva University Hospitals - Geneva (Switzerland), <sup>6</sup>Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva - Geneva (Switzerland)

2:40 p.m.

### **OC34: The MultiTEP-based vaccine, AV-1959R, safely elicits high concentrations of antibodies specific to Aβ42 protofibrils/fibrils/plaques in vaccinated healthy volunteers.**

Michael Agadjanyan<sup>1</sup>, Lon Schneider<sup>2</sup>, Alex Grinberg<sup>3</sup>, Anahit Ghochikyan<sup>4</sup>

<sup>1</sup>Nuravax, Inc./Institute for Molecular Medicine - Irvine (United States), <sup>2</sup>USC Keck School of Medicine - Los Angeles (United States), <sup>3</sup>Arvax, Inc. - Adelaide (Australia), <sup>4</sup>Institute for Molecular Medicine/Nuravax, Inc. - Huntington Beach (United States)



2:55 p.m.

### OC35: Clinical Performance of the Elecsys CSF pTau181/Aβ42 Ratio for Concordance with Tau-PET in Two Independent Cohorts

Ruben Smith<sup>1</sup>, Leslie Shaw<sup>2</sup>, Sebastian Palmqvist<sup>1</sup>, Niklas Mattsson-Carlgrén<sup>1</sup>, Gregory Klein<sup>3</sup>, Matteo Tonietto<sup>3</sup>, Clara Quijano-Rubio<sup>4</sup>, Christopher M. Rank<sup>5</sup>, Myrto Andreadou<sup>4</sup>, Samantha C. Burnham<sup>6</sup>, Erik Stomrud<sup>1</sup>

<sup>1</sup>Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden Memory Clinic, Skåne University Hospital, Malmö, Sweden - Lund, Malmö (Sweden), <sup>2</sup>Department of Pathology and Laboratory Medicine and the PENN Alzheimer's Disease Research Center, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, PA, United States - Philadelphia (United States), <sup>3</sup>Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland - Basel (Switzerland), <sup>4</sup>Roche Diagnostics International Ltd, Rotkreuz, Switzerland - Rotkreuz (Switzerland), <sup>5</sup>Roche Diagnostics GmbH, Penzberg, Germany - Penzberg (Germany), <sup>6</sup>Eli Lilly and Company, Indianapolis, IN, United States - Indianapolis (United States)

3:10 p.m.

### OC36: Biomarkers of Cognitive Performance in Alzheimer's Disease in Adults with Down Syndrome

Jason Russell<sup>1</sup>, Zinayida Schlachetzki<sup>1</sup>, Alexander Conley<sup>2</sup>, Brian Boyd<sup>2</sup>, Paul Newhouse<sup>2</sup>, Michael Rafii<sup>1</sup>

<sup>1</sup>Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), <sup>2</sup>Center for Cognitive Medicine, Vanderbilt University Medical Center - Nashville (United States)

3:25 p.m.

### OC37: The associations between cognitive deficits and the location of tau tangles and their consistency across clinical and observational datasets

Xingjian Zhang<sup>1</sup>, Ritobrato Datta<sup>1</sup>, Maggie Fedgchin<sup>2</sup>, Jennifer Bogert<sup>3</sup>, Janice Wong<sup>4</sup>, David Henley<sup>2</sup>, Gayle Wittenberg<sup>2</sup>, Ziad S. Saad<sup>1</sup>

<sup>1</sup>Johnson & Johnson - San Diego (United States), <sup>2</sup>Johnson & Johnson - Titusville (United States), <sup>3</sup>Johnson & Johnson, NJ - Raritan (United States), <sup>4</sup>Johnson & Johnson - Cambridge (United States)

3:40 p.m.

### OC38: Strategies for Increased Representation in Trials from The NIA Health and Aging Brain Study

Charisse Winston, University of Southern California - San Diego (United States)

3:55 p.m.

4:30 p.m.

### COFFEE BREAK AND POSTER SESSION (Indigo Ballroom – Level 2)

 **Biotech Showcase Session 6 – Late-Stage Biotech and Industry Innovations** (details P.28)

4:30 p.m.

6:00 p.m.

### ORAL COMMUNICATIONS

Moderators: Lon Schneider, Keck School Medicine of USC – Los Angeles, CA (United States) and Jacques Touchon, Montpellier University – Montpellier (France)

4:30 p.m.

### OC39: Estimated budget impact of a screening and treatment program for preclinical Alzheimer's disease in the U.S. over 15 years

Soeren Mattke<sup>1</sup>, Jiahe Chen<sup>1</sup>, Eric Reiman<sup>2</sup>

<sup>1</sup>University of Southern California - Los Angeles (United States), <sup>2</sup>Banner Alzheimer's Institute - Phoenix (United States)

4:45 p.m.

### OC40: Long-Term Nicotine Treatment of Mild Cognitive Impairment: The MIND Trial

Paul Newhouse<sup>1</sup>, Rema Raman<sup>2</sup>, Brenda Armenta<sup>2</sup>, Michael C. Donohue<sup>2</sup>, Michael S. Rafii<sup>2</sup>, Robert A. Rissman<sup>2</sup>, Edward Levin<sup>3</sup>, Kenneth Kellar<sup>4</sup>, Andrew Saykin<sup>5</sup>, Julie Dumas<sup>6</sup>, Patricia Andrews<sup>1</sup>, Rachel Tyndale<sup>7</sup>, Brian Boyd<sup>1</sup>, Paul Aisen<sup>2</sup>

<sup>1</sup>Vanderbilt University Medical Center - Nashville (United States), <sup>2</sup>University of Southern California - San Diego (United States), <sup>3</sup>Duke University - Durham (United States), <sup>4</sup>Georgetown University - Washington, Dc (United States), <sup>5</sup>Indiana University - Indianapolis (United States), <sup>6</sup>University of Vermont - Burlington (United States), <sup>7</sup>University of Toronto - Toronto (Canada)

5:00 p.m.

### OC41: Impact of Nutrition, Sleep and Physical Activity on Preservation of Intellectual Function in Older Frailty Adults (INSPIOR): A Randomized Controlled Trial

Sakurai Keisuke<sup>1</sup>, Izumi Shiraishi<sup>1</sup>, Ryo Tanaka<sup>1</sup>, Miwa Watanabe<sup>1</sup>, Momoko Funakawa<sup>1</sup>, Saori Shimada<sup>1</sup>, Tomoko Kawaura<sup>1</sup>, Toshiyuki Nomura<sup>2</sup>, Fuka Aoki<sup>3</sup>, Takashi Matsumoto<sup>3</sup>, Yukihiro Sugawara<sup>3</sup>, Hiroki Kayama<sup>4</sup>, Joseph Ledsam<sup>4</sup>, Shin'ichi Warisawa<sup>1</sup>, Tatsuhiro Hisatsune<sup>1</sup>

<sup>1</sup>The University of Tokyo - Kashiwa (Japan), <sup>2</sup>Mitsui Fudosan, Co., Ltd. - Kashiwa (Japan), <sup>3</sup>NH Foods Ltd. - Tsukuba (Japan), <sup>4</sup>Google - Tokyo (Japan)

5:15 p.m.

### OC42: Mapping the Pathogenesis of Alzheimer's Disease in Down Syndrome: Imaging, Fluid Biomarkers, Cognition, and Sex Differences for Clinical Trial Design

Nazek Queder<sup>1</sup>, Iris Chiang<sup>1</sup>, Andrew Luu<sup>1</sup>, Elizabeth Andrews<sup>1</sup>, David Keator<sup>2</sup>, Jenna N. Adams<sup>3</sup>, Lisa Taylor<sup>3</sup>, Michael Yassa<sup>3</sup>, Craig Stark<sup>3</sup>, Mark Mapstone<sup>4</sup>, Elizabeth Head<sup>1</sup>

<sup>1</sup>Department of Pathology & Laboratory Medicine, University of California, Irvine - Irvine (United States), <sup>2</sup>Department of Psychiatry and Human Behavior, University of California, Irvine - Irvine (United States), <sup>3</sup>University of California, Irvine - Irvine (United States), <sup>4</sup>Department of Neurology, University of California, Irvine - Irvine (United States)

5:30 p.m.

### OC43: Considerations for Phase 2 Trials of an A $\beta$ Vaccine, AV-1959R, for Secondary Prevention of Alzheimer's Disease

Lon Schneider<sup>1</sup>, Michael Agadjanyan<sup>2</sup>, Anahit Ghochikyan<sup>2</sup>

<sup>1</sup>Keck School of Medicine of USC - Los Angeles (United States), <sup>2</sup>Institute for Molecular Medicine - Huntington Beach (United States)

5:45 p.m.

### OC44: Tau positron emission tomography harmonization using the CenTauR approach: general conversion equations and external validation

Alexis Moscoso<sup>1, 2</sup>, Antoine Leuzy<sup>1, 3</sup>, Lau Raket Lars<sup>4</sup>, Victor L. Villemagne<sup>5, 6</sup>, Gregory Klein<sup>7</sup>, Matteo Tonietto<sup>7</sup>, Emily Olafson<sup>8</sup>, Ruben Smith<sup>9, 10</sup>, Fang Xie<sup>11</sup>, Hartmuth Kolb<sup>3</sup>, Nadine Tatton<sup>1</sup>, Yashmin Karten<sup>1</sup>, Christopher C. Rowe<sup>12, 13</sup>, Oskar Hansson<sup>9, 10</sup>, Vincent Doré<sup>12, 14</sup>

<sup>1</sup>Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute - Tucson (United States), <sup>2</sup>Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n - Santiago De Compostela (Spain), <sup>3</sup>Enigma Biomedical Group - Knoxville (United States), <sup>4</sup>Eli Lilly and Company - Indianapolis (United States), <sup>5</sup>Department of Psychiatry, University of Pittsburgh School of Medicine - Pittsburgh (United States), <sup>6</sup>Department of Molecular Imaging & Therapy, Austin Health - Victoria (Australia), <sup>7</sup>F. Hoffmann-La Roche Ltd - Basel (Switzerland), <sup>8</sup>Clinical Imaging Group, Genentech, Inc. - , South San Francisco (United States), <sup>9</sup>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University - Lund (Sweden), <sup>10</sup>Memory Clinic, Skåne University Hospital - Malmö (Sweden), <sup>11</sup>Department of Nuclear Medicine & PET Center, Huashan Hospital, University - Shanghai (China), <sup>12</sup>Florey Department of Neuroscience, University of Melbourne - Victoria (Australia), <sup>13</sup>The Australian Dementia Network (ADNeT), The University of Melbourne - Victoria (Australia), <sup>14</sup>Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO - Victoria (Australia)

6:00 p.m.

### END OF THE CTAD CONFERENCE

# ● BIOTECH SHOWCASE SESSIONS

## FLASH PRESENTATIONS DURING COFFEE BREAKS

As part of a new initiative at CTAD 2025, we are hosting dedicated Biotech Showcase Sessions — dynamic flash presentation slots where selected biotech companies will:

- Present their work in 3-minute / 3-slides lightning talks
- Engage in 3 minutes of live Q&A with moderators and attendees
- Gain expert feedback and investor attention
- Build high-value connections with leaders in AD clinical trials

Tuesday, December 2nd – 10:30 a.m. to 11:00 a.m.

### Session 1 – Artificial Intelligence and Digital Innovation

*Focus: AI platforms, digital biomarkers, virtual and mobile cognitive assessment.*

Moderators: Sandrine Andrieu, IHU HealthAge, Toulouse (France) and Lefkos Middleton, Imperial College London – London (United Kingdom)

1. **Prima Mente – AI neuroscience integrating data generation and clinical translation**  
Ravi Solanki, Prima Mente - San Francisco, CA (United States)
2. **Tolion Health – AI-driven brain health and longevity guidance app**  
Ondřej Lerch, Tolion Health - Prague (Czech Republic)
3. **Unlearn.AI – Digital twin platform for modern Alzheimer’s trials**  
Kwame Marfo, Unlearn AI - San Francisco, CA (United States)
4. **Indivi AG – Adaptive cognitive assessments with dynamic difficulty adjustment**  
Shibeshih Belachew, Indivi AG - Basel (Switzerland)

Tuesday, December 2nd – 3:50 p.m. to 4:20 p.m.

### Session 2 – Digital and Neurotechnology-Based Biomarkers and Therapeutics

*Focus: novel neurotech and at-home stimulation tools.*

Moderator: Michael Weiner, UCSF – San Francisco (United States)

1. **Nuuron GmbH – Ultra-high-frequency visual stimulation for memory enhancement**  
Fabian Queisner, Nuuron GmbH - Berlin (Germany)
2. **Clarity Health Technologies – VR-integrated 40Hz sensory stimulation**  
Carolina Reis, Clarity Health Technologies - Delaware (United States)
3. **REGENLIFE – Photomedical neurotechnology for brain–gut stimulation**  
Guillaume Blivet, REGENLIFE - Paris (France)
4. **Cumulus Neuroscience – Remote digital biomarkers for trial efficiency**  
Brian Murphy, Cumulus Neuroscience - Dublin (Ireland)

# BIOTECH SHOWCASE SESSIONS

FLASH PRESENTATIONS DURING COFFEE BREAKS

Wednesday, December 3rd – 10:55 a.m. to 11:25 a.m.

## Session 3 – Blood-Based Diagnostics and Biomarkers

*Focus: plasma and proteomic biomarker innovation.*

Moderators: Robert Rissman, ATRI – USC – San Diego, CA (United States)

1. **Diadem Inc. – AlzoSure® Predict plasma test (unfolded p53)**  
Shmuel Agus, Diadem Inc - Palo Alto (United States)
2. **Veravas – VeraBIND Tau plasma assay for active tau pathology**  
Josh Soldo, Veravas Inc - Austin (United States)
3. **betaSENSE GmbH – Immuno-infrared sensor detecting misfolded proteins**  
Klaus Gerwert, betaSENSE GmbH - Bochum (Germany)
4. **Taudia – Detection of low-abundance biomarkers for patient screening**  
Noah Elder, Taudia - San Carlos (United States)

Wednesday, December 3rd – 3:50 p.m. to 4:20 p.m.

## Session 4 – Multiomics and Precision Diagnostics

*Focus: Omics-based platforms and biomarker qualification.*

Moderators: Miranda Orr, Washington University in St. Louis – St Louis, MO (United States) and Howard Feldman, UCSD – San Diego, CA (United States)

1. **Agent – Multiomics blood biomarkers for Alzheimer’s drug development**  
Jérôme Braudeau, Agent - Evry (France)
2. **Washington University in St. Louis – Proteomic classifier for precision diagnosis**  
Carlos Cruchaga, Department of Psychiatry, NeuroGenomics and Informatics Center, Washington University School of Medicine - St Louis (United States)
3. **Fujirebio/ADx NeuroSciences – ADxPLOTTER qualified assays for early biomarker access**  
Charlotte Lambrechts, ADx NeuroSciences - Ghent (Belgium)
4. **Ricoh Biosciences – iPSC neuron panel for biomarker discovery**  
Marama Diaz-Asper, Ricoh Biosciences - Baltimore (United States)

# BIOTECH SHOWCASE SESSIONS

## FLASH PRESENTATIONS DURING COFFEE BREAKS

Thursday, December 4th– 10:30 a.m. to 11:00 a.m.

### Session 5 – Next-Generation Therapeutics

*Focus: novel small molecules, peptides, and new treatment modalities.*

Moderators: Jeffrey Cummings, UNLV – Las Vegas, NV (United States) and Bruno Vellas, IHU HealthAge – Toulouse (France)

1. **ProNeurogen Inc. – PNA5 first-in-class therapy for vascular dementia**  
Meredith Hay, ProNeurogen, Inc - Tucson (United States)
2. **Galimedix Therapeutics – GAL-101 Phase 1 oral small molecule**  
Alexander Gebauer, Galimedix Therapeutics Inc. - Kensington (United States)
3. **ChainGen Bio – BrainPortal peptides for blood–brain barrier transport**  
Hao Wu, ChainGen Bio - Shanghai (China)
4. **Anavex Life Sciences – Oral Blarcamesine Phase IIb/III trial results**  
David Gould, Anavex Life Sciences - New York (United States)

Thursday, December 4th – 3:55 p.m. to 4:30 p.m.

### Session 6 – Late-Stage Biotech and Industry Innovations

*Focus: advanced clinical programs and scalable biomarker platforms.*

Moderators: Laura Nisenbaum, Alzheimer's Drug Discovery Foundation, New York, NY (United States) and Jacques Touchon, University of Montpellier – Montpellier (France)

1. **AriBio Co. Ltd. – AR1001 Phase 3 neurodegeneration program (POLARIS-AD)**  
Fred Kim, AriBio Co., Ltd. - San Diego (United States)
2. **Beckman Coulter Inc. – Blood-based biomarker solutions for AD diagnostics**  
Kinal Bhatt, Beckman Coulter, Inc. - Chaska, Mn (United States)
3. **Advanced Brain Monitoring – BEAM™ mobile EEG/ERP platform for cognitive assessment**  
Chris Berka, Advanced Brain Monitoring - Carlsbad (United States)
4. **Sunbird Bio – EV-based plasma assay platform for non-invasive detection of modified  $\alpha$ Syn species**  
Vijay Parthasarathy, Sunbird Bio - Cambridge (United States)



# ● EARLY CAREER INVESTIGATOR SHOWCASE

## FLASH PRESENTATIONS DURING COFFEE BREAKS

Tuesday, December 2nd – 10:25 a.m. to 11:00 a.m.

### Category 1 – Translational Therapeutics and Clinical Innovation

Moderators: Rema Raman, USC-ATRI, San Diego (United States) and Michael Rafii, ATRI – USC, San Diego (United States)

1. **Michael Leuchter (UCLA)** – Broad Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus in Alzheimer’s Disease – **Poster PEC008**

*Exploring large-coil rTMS targeting the precuneus to improve brain network function and memory in Alzheimer’s disease through a two-stage feasibility trial.*

2. **Emily Clark (University of Rochester)** – Effects of Escitalopram on Neuropsychiatric Symptoms in Alzheimer’s Disease: S-CitAD Secondary Analysis – **Poster PEC002**

*Analyzing escitalopram’s effect on mood and caregiver distress, suggesting potential antidepressant and behavioral benefits in Alzheimer’s care.*

3. **Melissa Wong (University of Toronto / Sunnybrook Research Institute)** – Cerebral Blood Flow Ratio of the Default Mode Network to the Central Executive Network as a Predictor of Executive Function Following N-acetylcysteine Supplementation in Vascular Mild Cognitive Impairment – **Poster P162**

*Examining whether cerebral blood flow ratios can predict treatment response to N-acetylcysteine in vascular MCI, highlighting personalized neurovascular biomarkers for intervention response.*

Tuesday, December 2nd – 3:50 p.m. to 4:20 p.m.

### Category 2 – Biomarkers and Mechanisms of Frailty and Cognitive Decline

Moderators: Robert Rissman, ATRI – USC – San Diego, CA (United States) and Mark Espeland, Wake Forest University – Winston Salem, NC (United States)

1. **Davide Angioni (IHU HealthAge, Toulouse)** – Plasma p-tau181 Levels and Cognitive & Physical Decline in Frail Older Adults (CogFrail Study) – **Poster PEC001**

*Linking elevated plasma p-tau181 to both cognitive and physical decline, identifying a shared biological pathway for frailty and neurodegeneration.*

2. **Irina Skylar-Scott (Stanford University)** – Proteomic Signatures of Lifestyle Activities and Cognitive Reserve – **Poster PEC 003**

*Identifying plasma and CSF proteins associated with physical and cognitive activity, suggesting molecular pathways underlying resilience and cognitive reserve.*

- 3. Lara Herriott (University of Oxford / AC Immune SA) – Modeling Brain Exposure and Efficacy of Next-Generation Brainshuttle Antibodies – Poster P393**

*Developing a quantitative systems pharmacology model to predict brain exposure and efficacy of receptor-mediated transcytosis antibodies such as trontinemab, offering insights into amyloid clearance mechanisms.*

Wednesday December 3rd – 10:55 a.m. to 11:25 a.m.

### **Category 3: Digital Health and New Tools for Early Detection**

Moderators: Charlotte Teunissen, VUMC – Amsterdam (The Netherlands) and Anton Porsteinsson, University of Rochester Medical Center, New York, NY (United States)

- 1. Karra D. Harrington (Cogstate Ltd) – Feasibility and Accuracy of the LILA App for Community Cognitive Screening – Poster PEC006**

*Demonstrating the feasibility of a fully remote, AI-based verbal learning test for large-scale cognitive screening via smartphone.*

- 2. Giovanna Pilonieta (University of Alabama at Birmingham) – MRI Utilization for ARIA Response in Lecanemab-treated Patients – Poster PEC005**

*Investigating MRI monitoring practices in amyloid therapy, highlighting the clinical and economic implications of ARIA management.*

- 3. Marina Ritchie (ATRI, University of Southern California – San Diego) – Characterizing Enrollment Patterns in a Preclinical Alzheimer's Disease Trial – Poster P006**

*Analyzing enrollment dynamics and demographic factors influencing participation in a preclinical Alzheimer's disease trial, providing insights to optimize recruitment strategies and improve trial diversity.*

Wednesday December 3rd – 3:50 p.m. to 4:20 p.m.

### **Category 4: Non-Pharmacological and Lifestyle Interventions**

Moderators: Laura Baker, Wake Forest Alzheimer's Disease Research Center, Winston-Salem, NC (United States) and Joshua Grill, University of California, Irvine – Irvine, CA (United States)

- 1. Bon D. Ku (Catholic Kwandong University – South Korea) – Therapeutic Agriculture for Cognitive and Emotional Well-being – Poster P344**

*Evaluating gardening-based interventions as a novel, low-cost therapy to improve mood and executive function in older adults and dementia patients*

- 2. Inga Antonsdottir (Johns Hopkins University – United States) – Group Cognitive Behavioral Therapy for Insomnia (CBTi) in Dementia Dyads – Poster PEC004**

*Testing the feasibility of group CBTi tailored for persons with early Alzheimer's and their care partners, aiming to enhance sleep and reduce frailty.*

CTAD would like to thank its 2025 privileged partners for their continued support.

ULTIMATE SPONSOR



Alzheimer's  
**Drug Discovery**  
Foundation

PLATINUM SPONSORS



GOLD SPONSORS





## i PRACTICAL DETAILS

### CONFERENCE VENUE

Hilton San Diego Bayfront  
1 Park Boulevard, San Diego, CA 92101



*The Hilton is located just 3 miles (5km) from San Diego International Airport, easily accessible by taxi or Uber.*

## REGISTRATION DESK & BADGES PICK-UP



**Sapphire Foyer - Level 4**

### Opening Hours

- Mon, Dec 1: **9:00 a.m. - 6:00 p.m.**
- Tue-Thu, Dec 2-4: **7:30 a.m. - 6:00 p.m.**

*Badge required for all sessions and breaks.  
No reprints available.*

## HIGHLIGHTS

### Early Career Investigators Showcase

Short Flash talks during Coffee Breaks  
(see details p.90)

### NEW Biotech Showcase Sessions

3-min talks by emerging biotech companies,  
Q&A, and networking (see details p.87)

## Wi-Fi

**Network & Password: CTAD2025**

## LUNCH OPTIONS

Lunch not included. Nearby restaurants listed  
in the app and at the registration desk.

## CTAD WELCOME RECEPTION WITH THE SUPPORT OF THE ALZHEIMER'S ASSOCIATION

Monday, December 1 from 6:45 p.m. to  
7:45 p.m. in the Sapphire Ballroom  
(Level 4).



## PARKING

Both valet and self-parking are available  
on-site at the Hilton.

- Self-Parking: \$50.00 per day
- Valet Parking: \$65.00 per day

## ROOM LOCATOR



**LEVEL 5 - COBALT**  
Sponsors Meeting Rooms



**LEVEL 4 - SAPPHIRE**  
Registration Desk  
Conference Room (All sessions)



**LEVEL 3 - AQUA**  
Sponsors Meeting Rooms



**LEVEL 2 - INDIGO**  
Coffee Breaks  
Posters  
Showcases  
Business Suites  
Sponsors Meeting Rooms



**LEVEL 1 - PROMENADE**  
Meeting Room: The Pointe

## ● NOTES

This image shows a full page of white paper with horizontal dotted lines. The lines are evenly spaced and run across the width of the page, providing a guide for handwriting practice. There are no margins, text, or other markings on the page.

## ● NOTES

This image shows a full page of white paper with horizontal dotted lines. The lines are evenly spaced and run across the width of the page, providing a guide for handwriting practice. There are no margins, text, or other markings on the page.



# KEEP IN TOUCH!

Visit our brand new website

Follow us on Social Media



Subscribe to our newsletter

# SAVE THE DATE

A photograph of the Boston skyline, featuring numerous skyscrapers and buildings along the waterfront, with the city's reflection visible in the water below. The image serves as the background for the top half of the poster.

# CTAD

**2026**

Clinical Trials on Alzheimer's Disease

**November  
16-19, 2026  
Boston, MA (USA)**

[www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)

Email: [ctad@ant-congres.com](mailto:ctad@ant-congres.com)

**JPAD**  
THE JOURNAL  
OF PREVENTION  
OF ALZHEIMER'S  
DISEASE

